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1 INTRODUCTION 
Overweight is one of the major health problems related to the lifestyle of today's society, and recent 
scientific evidence indicates that the spread of overweight and obesity continues to increase 
dramatically throughout the world (Chopra et al., 2002 - King et al., 2009 - WHO, 2007). For the first 
time in history, there are more obese children than malnourished, an alarming fact considering that 
obesity is a high risk factor for the increased incidence of cardiovascular diseases, diabetes and 
tumors (Malvezzi et al., 2013 - Tamosiunas et al., 2014 - Wild et al., 2004). Thus, the prevention of 
weight gain has become increasingly important not only for everyday consumer health but also for 
those national or international institutions responsible for the health of their subjects. Today, people 
are becoming more and more interested in following a diet that allows them to reach, not only an 
adequate weight, but above all a good state of health. 
One of the dietary approach that has attracted particular attention in recent years is the “ketogenic 
diet” (KD). This is a dietary program designed in the 1920s as a therapy for drug-resistant epilepsy 
(Freeman et al., 1998 – Hartman & Vining, 2007), which then gained popularity in the 1970s as a 
weight-loss diet (Atkins) (Astrup et al., 2004 – Caminhotto et al., 2015). Indeed, many current diets 
are based on the KD model, and, recently, this model was proposed for a number of neurological 
disorders like Alzheimer’s and Parkinson’s diseases (Kashiwaya et al., 2015 – Vanitallie et al., 2005).  
But what actually is a "ketogenic" diet? The word “ketogenic” derives from the Greek and literally 
means ketones (chetos) origin (genesis), and the basis of the diet is to induce the synthesis of ketone 
bodies (KB), which take place of sugars for producing energy. This KB synthesis occurs essentially 
in two situations, fasting and diabetes. The fasting condition produces KB by forcing the organism 
to catabolize fats for energy, which through -oxidation leads to the production of large acetyl-CoA 
amounts that remain in excess compared to the available oxaloacetate. 
The KD is a high-fat, low-carbohydrates diet planned to achieve ketosis, characterized by increased 
levels of circulating KB. Under normal conditions and with a balanced diet, KB are produced in 
small quantities, but, under a KD, their synthesis is induced as a result of a very low carbohydrate 
intake and high fat intake. The low glucose supply stimulates the catabolism of fats to obtain 
energy, leading to the accumulation of acetyl-CoA and synthesis of KB by the liver, which are sent 
to the peripheral tissues where they are oxidized to produce energy (Fukao et al., 2004 – Laffel, 1999 
– Nehling, 2004). 
This physiological process represents an evolutionary advantage for the human species, which was 
exposed at its origins to cycles of glut, prolonged fasting and frequent famine. The big question 
today is: are there any risks to taking advantage of this metabolic response in order to obtain weight 
loss? This is a subject of heated debate by the scientific community. Indeed, the usefulness of KB for 
therapeutic purposes is unquestionable, since its positive effects are now recognized in the 
treatment of epilepsy and other neurodegenerative diseases. However, as a solution to rapid weight 
loss the ketogenic dietary approach requires further attention. 
 
1.1 SYNTHESIS OF KETONE BODIES 
Three compounds are called "ketone bodies": acetoacetate (AA), -hydroxybutyrate (HB) and 
acetone (Fig. 1). AA is produced and used, during intermediate metabolism, and it generates the 
other two KB. Acetone, which derives from the spontaneous decarboxylation of AA, is of clinical 
interest because its particular smell in the exhaled air allows the identification of ketosis. Instead, 
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HB is produced from the reduction of AA, and is conventionally grouped with the other two KB, 
although HB’s ketone part is reduced to hydroxyl group. HB is not volatile and is chemically 
stable, one of its metabolic fates being interconversion with AA (Fukao et al., 2004). 
 
Fig. 1 Chemical structure of ketone bodies.  
Under normal conditions and with a balanced diet, KB are produced in small quantities, because 
acetyl-CoA is mainly used in the citric acid cycle. The oxidative decarboxylation of pyruvic acid and 
-oxidation are specifically regulated so that acetyl-CoA is not produced in excess. The main uses of 
acetyl-CoA (Fig. 2) shall include its complete oxidation to CO2 and H2O in the mitochondria, and its 
cytosolic utilisation for the biosynthesis of fatty acids and cholesterol.  
 
Fig. 2 Metabolic uses of acetyl-CoA. 
One of the factors on which mitochondrial oxidation of acetyl-CoA depends is the mitochondrial 
levels of oxalacetate, generated mainly by the decarboxylation of pyruvic acid, the terminal product 
of glycolysis, and the metabolism of some aminoacids. Indeed, acetyl-CoA and oxaloacetate are 
condensed to form the citrate, which is used in the citric acid cycle of mitochondria, or exported to 
cytosol.  
Under particular conditions, like when the intracellular glucose levels become too low, for example 
during prolonged starvation, fasting or as a result of low insulin levels in diabetes, oxaloacetate is 
depleted owing to its preferential utilization in the process of gluconeogenesis. This impedes the 
entry of acetyl-CoA into Krebs cycle. Therefore, in liver mitochondria, the excess of acetyl-CoA is 
converted into KB, which are sent through the bloodstream to the peripheral tissues where they are 
oxidized to produce energy, or excreted in the urine (Campbell & Farrel, 2012).  
The mitochondrial synthesis of KB consists of three steps (Fig. 3): 
 the first step is the enzymatic condensation of two molecules of acetyl-CoA, catalyzed by 
thiolase; 
 the acetoacetyl-CoA condenses with acetyl-CoA to form β-hydroxy-β-methylglutaryl-CoA 
(HMG-CoA); 
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 HMG-CoA is cleaved to free AA, which is reversibly reduced by D-β-hydroxybutyrate 
dehydrogenase to βHB, or spontaneous decarboxylated to acetone. 
 
Fig. 3 Ketogenesis pathway. 
The use of KB for energy purposes occurs in physiological conditions, such as morning ketosis, 
ketosis after effort or after eating a low-carbohydrates and high-protein meal (Pezzana et al., 2014). 
This physiological ketosis differs a lot from diabetic ketoacidosis, a severe status in which KB are 
over-produced by the liver. In fact, circulating levels of KB in normal conditions are generally 0,5 
mM, while on a KD they are up to 5-7 mM, and in uncontrolled diabetes they can reach up to 25 
mM. Moreover, the normal ratio between HB and AA is 3:1, while on a KD it can reach 4:1, and in 
diabetic ketoacidosis 6:1 (Tab. 1) (Cahill, 2006 - Laffel, 1999).  
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 Physiological condition Ketogenic diet Diabetic acidosis 
Circulating levels of KB 0,5 mM 5 - 7 mM 25 mM 
HB : AA ratio 3 : 1 4 : 1 6 : 1 
Tab. 1 Different KB’s circulating levels and HB : AA ratio in the bloodstream. 
When the amount of KB exceeds normal values in the blood (up to 3 mM) a metabolic 
decompensation takes place. KB are relatively strong organic acids that are potentially harmful 
because they lower blood pH below regular values, causing acidosis. It is important to note that 
prolonged acidosis can become a dangerous pathology, and is, in fact, the first cause of death of 
prolonged fasting, and can also be a severe consequence of uncontrolled diabetes. Buffer systems 
usually stabilize the body's pH, but if the fast conditions persist, they become exhausted and the pH 
reaches a non-optimal level for many enzymes. Moreover, the excessive amount of urine produced 
by kidneys to expel KB can produce a secondary imbalance of mineral salts (Campbell & Farrel, 
2012). 
 
1.1.1 Metabolic effects of ketone bodies 
KB are emerging as crucial regulators of human health. For instance, HB could be a valid energy 
support for peripheral tissues during fasting or intense physical exercise. Human HB basal serum 
levels are normally low, about 0,1 mM, but after two days of fasting they can reach 1-2 mM, and 
under ketogenic treatment can even exceed 2 mM concentration (Kim & Rho, 2008). Intriguingly, 
HB is more than just a metabolite as it also plays an important cellular signalling role. In fact, HB 
is an endogenous inhibitor of histone-deacetylases (HDACs) and a ligand for at least two cell 
surface receptors that modulate lipolysis, sympathetic tone and metabolic rate (Fig. 4).  
 
Fig. 4 Cellular signaling functions of the ketone body OHB (HB) (Newman & Verdin, 2014)  
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In addition, HB alters protein acetylation through at least two mechanisms: i) by increasing the 
cellular pool of acetyl-CoA that is a substrate for histone acetyltransferases, and ii) by directly 
inhibiting the activity of class I HDACs (Newman & Verdin, 2014). HDACs are a family of proteins 
able to suppress gene expression through the deacylation of lysine residues of histone and 
non-histone proteins. The ability of HB to affect HDAC activity, and thereby epigenetic regulation, 
can have notable implications on a wide variety of genes. For instance, HB is able to modify the 
expression of genes involved in resistance to oxidative stress (acting in particular on HDAC-1) 
(Giacco & Brownlee, 2010) or in the development of metabolic diseases (Mihaylova et al., 2013). 
Thus, the ability of HB to induce resistance to oxidative stress by inhibiting HDACs could explain 
the therapeutic benefit of a KD for neurological disorders (Newman & Verdin, 2014). 
Antioxidant and oxidative stress-mitigating roles of KB have been widely described both in vitro 
and in vivo, particularly in the context of neuroprotection. 
In this regard, Noh and colleagues showed (2016) how KB, particularly AA, offer protection from 
oxidative stress caused by glutamate. In fact, the results indicated that both AA and HB 
significantly reduce glutamate-induced neuronal death in HT22 cells (a mouse hippocampal cell 
line) and in rat primary hippocampal neurons. Specifically, it was seen that pre-treatment with 5 
mM of AA provided more effective HT22 protection (about 86%), than that offered by HB (52%). 
Instead treatment with acetone provided no protection. Moreover, the effect of AA on ROS 
production was assessed; the data showed that a treatment for 8 hours with glutamate in HT22 
leads to an increase in ROS levels, while the pre-treatment with AA has significantly decreased ROS 
production. Therefore, the results suggest that, in this in vitro model, the neuroprotective effect of 
AA is related to the decrease of mitochondrial ROS production (Noh et al., 2006). 
 
1.2 KETOGENIC DIET FOR THERAPEUTIC PURPOSES 
1.2.1 Epilepsy 
To date, it has been demonstrated how the metabolic state of mild ketosis, which can be induced 
through KD administration, calorie restriction or fasting, represents an emerging tool for the 
metabolic management of epilepsy and a number of different neurological and metabolic diseases.  
Epilepsy represents one of the most frequent neurological pathologies, concerning about 43 million 
people worldwide. The annual incidence of epilepsy is 40-70 cases per 100,000 people in 
industrialized countries and 100-190 per 100,000 in resource-poor countries (Fig. 5). 
 
Fig. 5 Representation of the incidence of epilepsy (number of cases per 100,000 inhabitants) in the different 
countries of the world (Abramovici & Bragic, 2016). 
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In most cases, epilepsy is considered a benign condition: in fact, in 60% to 70% of diagnosed cases a 
remission is obtained after appropriate treatment with anti-epileptic drugs. However, 30-40% of 
patients with epilepsy do not respond to any antiepileptic treatment (Kwan & Brodie, 2000). 
Evidence suggests that the incidence of drug-resistant epilepsy is high: it has been reported that up 
to 525 individuals (9-93 years) presented with a new diagnosis of epilepsy, 37% having being shown 
to be drug resistant after 13 years of pharmacological treatment (French, 2007). Currently, KD is 
recognized as the best protocol to treat drug-resistant epilepsies. 
It has been known for a long time that fasting can be used as a treatment for epilepsy; descriptions 
of the effectiveness of dietary restriction for this purpose date back to the time of Hippocrates and 
are mentioned in the New Testament. High-fat diets were considered about 150 years ago, but the 
first recognized therapeutic use of the diet seems to have been in the United States at the beginning 
of the last century, when a healer (Bernard Macfadden) and an osteopathic physician (Dr. Hugh 
Conklin) supported the use of fasting in a boy with epileptic seizures. As soon as human 
metabolism became better understood, it became clear that a high-fat diet could induce, like fasting, 
a state of ketosis. Simultaneously, Wilder introduced the concept of a diet composed of "ketogenic" 
and "anti-ketogenic" components for the treatment of epilepsy (Wilder, 1921). About 20 years ago, 
the treatment of a child at the Johns Hopkins Hospital raised worldwide scientific interest in KD 
(Freeman et al., 1998).  
Therapeutic KD is high in fat content and low in carbohydrates. When carbohydrates are limited, 
ketones, responsible for the anticonvulsant action, are synthesized to provide an alternative fuel 
source to the brain. The typical ratio between fats and carbohydrates plus proteins (in terms of 
grams) is 4:1 (Kossoff & McGrogan, 2005). The efficacy of the KD against epilepsy has been 
demonstrated by taking into consideration a series of parameters, similar to those of patients in 
pharmacological treatment, such as seizure control and the absence of side effects. Currently, the 
classic KD and its variants are used in the treatment of drug-resistant epilepsy in 80 countries (2017) 
all over the world. 
 
1.2.2.1 Dietary protocols 
The diet is aimed at inducing and maintaining ketosis. The types of dietary protocols used up to 
now are distinguished i) by the way in which ketosis is induced and ii) based on the quality and 
quantity of the lipid and carbohydrate components. In summary, they can be grouped as follows 
(Tab. 2); 
Protocol  
Classic Long chain triglycerides, caloric and fluid restriction, induction of fasted ketosis  
Classic  
updated 
Long or medium-chain triglycerides (MCT), without fasting, without caloric and 
liquid restriction 
Alternative With increased carbohydrate content (MAD, LGIT) 
Tab. 2 Main ketogenic protocols. 
The classic KD is the original diet introduced into practice in the 1920s. It is typically composed of a 
4:1 ratio of fat (in grams) to protein plus carbohydrates (in grams), thus shifting the predominant 
caloric source from carbohydrate to fat. Lower ratios of 3:1, 2:1, or 1:1 can be used depending on age, 
individual tolerability, levels of ketosis, and protein requirements (Zupec-Kania & Spellman, 2008). 
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In addition, different and more relaxed variant forms (Fig. 6) have been designed, including the KD 
combined with medium-chain triglycerides (MCT), the Modified Atkins Diet (MAD) and the Low 
Glycemic Index Treatment (LGIT). 
  
Fig. 6 Different diet compositions (%/kcal): classic KD and its variants. 
The KD MCT variant uses medium-chain fatty acids provided by coconut and/or palm kernel oil as 
a diet supplement. Replacing part of the long-chain triglycerides (LCT) with MCT is a composition 
variant introduced in 1971 by Huttenlocher in Chicago. This variant increases the share of 
carbohydrates as MCT results in more ketones per kcal of energy than LCT, are absorbed more 
efficiently, and are carried directly to the liver in the portal blood. This increased ketogenic potential 
means less total fat is needed in the MCT diet, allowing the inclusion of more carbohydrate and 
proteins. The ketosis level achieved is similar to that of the classic protocol and, moreover, the diet 
with MCT has proved to be equally effective in the treatment of epilepsy (Neal et al., 2009).  
The MAD variant, introduced in 2003, is based on a ratio of approximately 1:1, although this is not 
necessary in all meals, and includes 10-30 g of carbohydrate per day with no restriction of fluids, 
calories or protein. It allows users more flexibility and it does not require the calculating and 
weighing of food portions or an initial hospital stay for its implementation (Kossoff et al., 2008).  
The LGIT is designed to prevent dramatic postprandial increases in blood glucose by limiting the 
quantity of carbohydrates consumed and restricting the carbohydrates sources to low glycemic 
index foods (< 50 GI). Compared to the classic KD, the LGIT variant allows for a less restricted total 
carbohydrate intake (Muzykewicz et al., 2009 - Pfeifer & Thiele, 2005). 
The general protocol of the classic KD adopted at the Johns Hopkins Hospital (Tab. 3) has evolved 
over time, and many advances have been made regarding the mode of administration of the diet. 
Before beginning it, the patients are subjected to tests aimed at identifying any metabolic disorders 
that might interfere with the ability to generate adequate ketone amounts, like defective metabolic 
pathways of oxidation or fatty acids transport. However, there are some absolute contraindications 
to KD and these include pyruvate carboxylase deficiency, porphyria, lipid myopathies, and primary 
or acquired carnitine deficiency (Hartman & Vining, 2007 – Wheless, 2001). 
Once admitted to hospital, the patients are fasted (fluids are administered) with glycemic controls 
every 6h. For glucose levels below 25-40 mg/dL, no treatment is needed unless the patient becomes 
symptomatic (for example with extreme lethargy and severe vomiting). On the second day 2/3 of 
the total calories programmed are administered, and on the third day, the total caloric intake 
calculated. The total amount of calories of the diet is based on anthropometric measures and dietary 
habits of the subject prior to the intervention. 
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Tab. 3 Typical KD initiation regimen (Hartman & Vining, 2007) 
The typical diet, in the clinic, includes 3 meals and 2 snacks during a period of 24h (Tab. 4).  
 
Tab. 4 Example of daily menu of KD (Hartman & Vining, 2007) 
The next phase of the KD consists of routine clinical visits (3, 6, 12, 18 and 24 months after beginning 
the diet) with laboratory tests and frequent meetings with the nutritionist. In general, once the 
efficacy of the diet has been established (usually within 3-6 months from the start of the diet), the 
drugs are reduced. However, if the patient has significant side effects from the drug therapy, the 
drugs can be eliminated earlier (Kossoff et al., 2004). 
 
1.2.1.2 Side effects & complications 
The KD is an effective medical therapy for epilepsy, but it must be carefully monitored because it is 
associated with a number of side effects. A recent review was aimed at retrieving prospective 
studies that monitored adverse effects in children receiving KD therapy for refractory epilepsy (Cai 
et al., 2017). It reported that more than 40 categories of side effects are associated with KD (Tab. 5). 
Some are predictable and potentially curable, such as constipation, dehydration, and hypoglycemia 
(Kang et al., 2004), others, such as cardiomyopathy and renal tubular acidosis, have been reported in 
isolated clinical cases, and their relationship with KD is unknown. 
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Tab. 5 Reported adverse effects due to the KD in prospective studies (n=1376) (Cai et al., 2017) 
One of the side effects that has been systematically detected is nephrolithiasis (observed in 6% of 
patients) (Furth et al., 2000); while other adverse effects of the diet are hypercalciuria, aciduria and 
hypocitruria which contribute to the formation of stones. For these reasons all the patients, before 
starting the diet, are screened for family history of nephrolithiasis and hypercalciuria. For those 
having high amount of creatinine, calcium in the urine and haematuria, or those taking carbonic 
anhydrase inhibitors, oral citrate salts were prescribed as prophylactic (Kossof et al., 2002). Finally, 
nephrolithiasis is treated by increasing fluid intake, alkalinisation of urine, and suspension of 
carbonic anhydrase inhibitors. 
For very young children following the protocol, one consequence to be taken into consideration is 
the fact that growth (height and weight) may be compromised (Liu et al., 2003). Thus during the 
follow-up visits each child’s growth is monitored and strictly controlled. During the admission 
phase of the diet, families are informed about the symptoms of possible side effects, though many 
such effects do not manifest themselves immediately but have long-term implications. In fact, there 
could be consequences for the health of the vascular system (atherosclerosis), bones (osteoporosis), 
and liver (Hartman & Vining, 2007). 
In addition to a potential decrease in the children’s growth, there can also be reduced bone mineral 
density due to the limited availability of calcium in the diet. Recently, an animal model study was 
conducted (Frommelt et al., 2014) to determine mineral absorption in a KD compared to a diet with 
a standard fat content. It was demonstrated that calcium absorption was considerably reduced in 
KD, suggesting a lower bioavailability of the mineral. Indeed, in 2008 a longitudinal intervention 
study addressed this issue by assessing the bone mineral content (BMC) in epileptic children. The 
subjects were 25 pre-adolescent children (1-14 years, 16 males and 9 females) undergoing a 
ketogenic regimen for 15 months. Along with BMC, other parameters were measured, such as 
anthropometric data, vitamin D, parathyroid hormone and electrolytes. The results were compared 
with a cohort of 847 healthy children. The results of this longitudinal study indicated that children 
with refractory epilepsy had, at baseline, compromised bone health and suboptimal growth status. 
During the observation period, a progressive loss of bone mineral content was detected, resulting 
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in osteopenia and osteoporosis despite the increased serum levels of vitamin D. Bone health in 
children with intractable epilepsy was poor, particularly for younger non-ambulatory children 
with low BMI status (Bergqvist et al., 2008). 
Consideration must be given to the fact that the ketogenic therapeutic regimen is administered for 
a long time (>2-3 years). In this regard, Groesbeck and colleagues conducted a retrospective study 
of 28 children treated with the KD for 6-12 years; they reported that 21% had bone fractures. In 
particular, the first fracture occurred after only 1.5 years (median of the cases) from beginning the 
diet, and 14% of the subjects had, in their medical history, more fractures (Groesbeck et al., 2006) . 
 
1.2.1.3 Anti-seizure effects of ketogenic diet 
Despite the passing of a century since the first application of a KD, and the wide recognition of its 
efficacy, its mechanisms of action are only now being studied. In recent years, many hypotheses 
have been formulated to explain the anti-seizure effects of the KD. At present, it is becoming more 
apparent that the KD maybe works through multiple mechanisms that target fundamental 
biochemical pathways linked to cellular substrates and mediators responsible for neuronal 
hyperexcitability.  
Fig. 7 shows a schematic summary of the principal mechanisms currently believed to be responsible 
for the anti-seizure activity of this dietary therapy. The most important effects, induced by ketosis, 
which have been accepted by the scientific community, are as follows (Rho, 2017): 
- changes in neurotransmitter systems, including GABA, glutamate, and adenosine, as well 
as ion channel regulation. For instance, KB have been proposed to increase levels of GABA and 
enhances inhibitory neurotransmission by altering the metabolism of glutamate (Yudkoff et al., 
2005). In addition, the activation of some ione-channles, such as ATP-sensitive potassium channels 
and two-pore domain channels, would hyperpolarize neurons and decrease neuronal excitability 
as well. In this respect, Ma and colleagues (Ma et al., 2007) demonstrated that, at physiological 
concentrations, KB reduce spontaneous discharges of GABAergic neurons in the rat substantia 
nigra, through ATP-sensitive potassium channels. 
- enhancement of cellular bioenergetics and mitochondrial function; the mitochondrial 
biogenesis is predicted to increase ATP production and enhance energy reserves, leading to 
stabilized synaptic function and improved seizure control. Moreover, a remarkable increase in 
mitochondrial transcription proteins and enzymes was observed in rat hippocampus after the 
administration of a KD (Bough et al., 2006). 
- glycolytic restriction or diversion; the KD also induces a small reduction in glycolysis, 
concomitant with an increase in non-glucose sources of fuel through the oxidation of fatty acids 
and KB. Thus, glycolytic restriction is thought to be an important mechanism mediating the 
anti-seizure properties of the KD. 
- direct inhibitory action of fatty acids; intake of a high-fat diet increases the rate of fatty acid 
oxidation and this also changes the levels and types of polyunsaturated fatty acids (PUFAs) in the 
circulation, liver and brain. Since PUFAs are known to possess neuroprotective properties 
(Michael-Titus & Priestley, 2014), it has been assumed that this lipid species may help mediate the 
anti-seizure effects of the KD.  
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Fig. 7 Hypothetical pathways leading to the anticonvulsant effects of the KD (Rho, 2017).  
[adenosine receptors: A1R - -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor: AMPAR - 
brain-derived neurotrophic factor: BDNF - brain-specific uncoupling proteins: UCPs -–peroxisome 
proliferator-activated receptor-: PPAR - peroxisome proliferator-activated receptor  coactivator-1: PGC-1 - 
polyunsaturated fatty acids: PUFAs - vesicular glutamate transporters: VGLTs] 
1.2.3 Specific epilepsy syndromes 
Traditionally, the KD has been widely used in cases of drug-resistant epilepsy, but it has also 
become established as a therapy for a few specific epilepsy syndromes. 
The glucose transporter type-1 deficiency syndrome (GLUT1-DS) was first described by De Vivo et 
al. quite recently (De Vivo et al., 1991), but no firm estimates of its incidence and prevalence can be 
made as the cases have been reported worldwide and are biased by physician awareness of the 
disorder. In Queensland, Australia, it was estimated that the incidence/prevalence is approximately 
1:90,000, data are supported by a more recent Scandinavian study that reported a similar 
incidence/prevalence of 1:83,000 (Larsen et al., 2015). In Italy, there is no national registry of 
GLUT1-DS so the prevalence cannot be estimated (De Giorgis et al., 2015). This disease is caused by 
impaired glucose transport across the blood-brain barrier and into brain cells. The majority of 
patients carry heterozygous mutations in the SLC2A1 gene encoding the GLUT1 transporter 
(Awaad et al., 2015). If not identified and treated, children with GLUT1-DS develop microcephaly, 
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mental retardation, spasticity, and ataxia as a consequence of relative brain hypoglycemia. 
Currently, this epilepsy syndrome is effectively treated with KD, because the KB generated from 
dietary fatty acid oxidation are able to penetrate the blood-brain barrier and provide an alternative 
fuel for the central nervous system. As the developing brain of young children requires a lot of 
energy, the KD should be started as early possible, and should be maintained into puberty (Klepper, 
2008). Even though KD is the first choice of treatment in GLUT1-DS patients, about 20% of such 
patients do not meet the compliance criteria or the diet loses its effectiveness over time, so for these 
reasons new therapeutic strategies need to be identified (Veggiotti & De Giorgis, 2014). 
Similarly, children with pyruvate dehydrogenase complex (PDC) deficiency show improvements 
while on the KD. In PDC deficiency, pyruvate, the glycolytic end product, is not optimally 
metabolized through the tricarboxylic acid cycle, and this leads to an increased production of lactate 
and limited mitochondrial energy production (Patel et al., 2012). A recent Swedish publication 
reported a longitudinal cohort study of pediatric patients diagnosed with PDC deficiency and 
treated with KD. All the patients suffering baseline epileptic seizures improved during KD 
treatment.; half of them stopped having seizures within 1 year of starting the diet. Based on the 
results, the authors proposed that KD should be introduced as soon as possible after diagnosing 
PDC deficiency, as early initiation could prevent further metabolic injury to the brain. Moreover, 
they reported that the long-term effectiveness is highly dependent upon the condition of ketosis, 
which must be regularly assessed by monitoring the plasma ketone levels and adjusting dietary 
composition (Sofou et al., 2017). 
One of the most malignant epileptic syndromes in which this specific diet may be particularly 
useful is the severe myoclonic epilepsy of infancy also known as Dravet syndrome (DS), which is 
associated in many cases with mutations in the gene SCN1A, a subunit of the sodium channel of 
muscle cells and neurons (Steel et al., 2017). DS is characterized by the onset of febrile hemiclonic or 
generalized status epilepticus in the first year of life. Febrile seizures recur, followed by the 
evolution of afebrile seizures including myoclonic, absence, and partial seizures between ages 1 and 
4 years. The epilepsy is usually resistant to standard antiepileptic medication, and from the second 
year of life cognitive, behavioural, and motor impairments become apparent (Dravet, 1978 – Dravet, 
2011). In 2006, a retrospective study evaluated the efficacy and tolerability of the KD in 13 patients 
with DS; ten of them had a significant reduction in the number of seizures. Considering the 
intractability of seizures in patients with DS, this result has shown that the KD is an attractive 
therapeutic alternative (Caraballo et al., 2006). More recently, another retrospective study evaluated 
both KD effectiveness and tolerability in comparison with multiple antiepileptic drugs. According 
to the results reported, such as good effect on seizures, good tolerability and few compliance 
problems due to formula treatment, the KD should be considered an early treatment option in 
infants with DS. In fact, data showed equal efficacy of the KD compared with various antiepileptic 
drugs currently available for the treatment of DS (Dressler et al., 2015). 
1.2.4 New applications 
Recently, the use of the KD has been proposed in a series of pathological conditions quite different 
from epilepsy syndromes. 
For instance, in neurodegenerative disorders KD has been shown to have a positive effect, although 
it is not completely clear whether this is direclty due to the KD or wheter it is due to the metabolic 
changes the diet induces (Barañano & Hartman, 2008).  
13 
 
Parkinson’s disease (PD), a condition in which the neurotoxine 
1-methyl-4-phenyl-1,2,3,6-etrahydropyridine (MTPT) causes dopaminergic neurodegeneration, has 
been shown, through an animal model, to benefit from a protective HB action, an effect that could 
be related to improved mitochondrial respiration and ATP production (Jabre & Bejjani, 2006 – 
Vanitallie et al., 2005). Additional evidence supporting the potential benefits of KB in PD is provided 
by another in vitro study demonstrating neuroprotective and anti-inflammatory effects of KD 
against MPTP-induced-neurotoxicity (Yang & Chen, 2010).  
Also Alzheimer’s disease has been found to benefit from the protective role of KB in that it can 
decrease amyloid -peptide, which, in this progressive dementia, accumulates in brain regions 
critical for memory (Kashiwaya et al., 2013). Furthermore, a pilot clinical study involving 15 
Alzheimer participants has shown that KD can actually improve memory in cognitively intact 
subjects, or subjects with mild cognitive impairment (Taylor et al., 2018). 
Moreover, KD has emerged as a potential treatment for autism spectrum disorder (ASD). Since ASD 
is associated with metabolic dysfunction and autism is a common trait of epilepsy-associated 
diseases, the use of KD has been suggested to ameliorate some of the ASD-associated symptoms. In 
fact, one study and one case report indicated that children with ASD treated with a KD showed 
decreased seizure frequencies and exhibited behavioural improvements (Napoli et al., 2014). Indeed, 
a more recent clinical trial was done to test a modified KD for the improvement of core clinical 
impairments in 15 children with ASD (Lee et al., 2018), and it was found that components of the KD 
are possibly beneficial in improving social skills in children with ASD. However, additional studies 
are needed to understand how the KD improves behavior, because the mechanism of action is still 
unidentified.  
Currently, there is the proposal that KD might prevent tumor progression and could be used as 
supportive therapy in patients with different type of cancer. The mechanism underlying this 
hypothesis is the fact that cancer cells require large amounts of glucose; in fact, cancer cell 
mitochondria are dysfunctional, so they cannot use fatty acids and KB, which, on the contrary, can 
be used by healthy cells. The goal of KD is to limit sources of energy for cancer cells by restricting 
carbohydrates, while providing fatty acids and KB to healthy cells (Seyfried et al., 2014). A 
systematic review of 13 studies evaluated the KD effects on survival time and tumor growth in 
animal models. From these studies, 9 articles indicated that KD significantly increased the mean 
survival time and there was a clear trend of slower tumor growth in pancreatic, prostate, gastric, 
brain, lung cancer (Khodadadi et al., 2017). However, few human data are available, and these 
provide little concrete evidence of the anti-tumor effects of KD, due to the lack of controlled trials 
and the limitation to individual cases (Klement, 2017).   
 
1.3 KETOGENIC DIET FOR WEIGHT LOSS 
Currently, the KD as a weight loss dietary protocol (e. g. Atkins) is one of the most discussed issues 
by the scientific community. Although this diet seems to promote a better control of hunger and a 
greater weight loss in the short time, it differs quite radically from the conventional guidelines for 
healthy diet (Fig. 8), and the long-term effects on health and disease risks need clarification.  
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Fig. 8 Macronutrient’s percentage contributions to daily caloric intake of Atkins diet compared to American 
recommendation (Astrup et al., 2004). 
The cardiologist Robert C. Atkins was the first to propose the KD with an aim different from the 
therapeutic one. He devised it in the ‘70s to prevent diabetes, however the diet became famous for 
its effectiveness in weight loss. The Atkins protocol applied with the purpose of weight control 
consists of 4 phases:  
1 - the first is the induction phase, recommended for 2 weeks, where the aim is to bring the 
organism into ketosis. The intake of carbohydrates is limited to 20-25 grams daily, of which 12-15 
grams must come from salad leaves, fruits and vegetables such as broccoli, spinach, pumpkin, 
cauliflower, tomato (legumes are not allowed at this stage because they are too rich in starche). 
Among the permitted foods, meat can be eaten ad libitum, as well as fish, shellfish and eggs. 
2 - this second phase is still characterized by the strict control of carbohydrate intake, but gradually 
increasing it by 5 grams a week (the consumption of some fruits and legumes is granted).  
3 - the carbohydrate intake is increased further, up to 10 grams a week. The goal is to find the 
amount of carbohydrates that allows to maintain the proper weight without getting fat. 
4 - in the last phase the objective is to consolidate the eating habits adopted in the previous stages. 
Although an instinctive choice of food is encouraged, the regaining of weight means that the subject 
must return to the previous phases (Atkins, 2002). 
The Atkins diet books have sold over 45 million copies in over 40 years and, given today’s obesity 
epidemic, both the Atkins diet and its associated products are still very popular worldwide. This 
diet protocol promises to lose weight effectively despite the ad libitum consumption of meat, butter 
and other high-fat dairy products, while limiting carbohydrate intake to less than 30 grams/day. 
The apparent paradox that the unlimeted intake of fatty foods produces weight loss seems to be due 
to various reasons: the severe limitation of carbohydrates depleting glycogen stores, the suppressed 
appetite by the ketogenic nature of the diet, the satiating power of the high-protein content, the 
reduction of spontaneous food intake which leads to a reduction in energy intake, and finally, as the 
protocol is hypocaloric, the catabolism of fatty acids by -oxidation (Astrup et al., 2004).   
1.3.1 Ketogenic diet vs low-fat diet 
The differences in health benefits of carbohydrate-restricted diet and a calorie- and fat-restricted 
diet are of considerable public interest. There are concerns that a very-low-carbohydrate-diet 
(VLCD) leads to abnormal metabolic functions that could have a severe impact on human health. 
For this reason, many in vivo studies, meta-analyses and reviews have been published to 
understand the short- and long-term effects of a VLCD compared to other more conventional diets. 
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Is it really so beneficial to follow a restrictive diet like VLCD? What is the effectiveness of this 
dietary protocol in the long-term? 
In 2003, three different randomized trials evaluated the effect of VLCD on several parameters, 
focusing on wight loss, compared to other types of diet. In the first study, 132 severely obese 
individuals (39% affected by type II diabetes, 43% by metabolic syndrome) were randomly divided 
into two groups and assigned to a low-carbohydrate diet (LCD) or a low-fat diet (LFD). After 6 
months, subjects undergoing the LCD had lost 3.9 kg more than the other group (Samaha et al., 
2003). In the second study, which lasted 6 months as well, 53 obese women followed a VLCD or a 
low-calorie diet with 30% of fat energy. At the end of the treatment, the women who had followed 
the VLCD had lost more weight than those who followed the low-calorie diet (-8.5 kg vs. -3.9 kg, p 
<0.001) (Brehm et al. , 2003). The third study was conducted for 12 months, on 63 non-diabetic obese 
subjects who followed Atkins diet or a conventional hypocaloric diet (25% of the energy from fats, 
15% from proteins and 60% from carbohydrates). After 6 months the Atkins group showed better 
results, with a weight loss of 7% of body weight, compared to 3.2% of the other group (p < 0.02); 
however, after 1 year the difference between the groups was no longer significant (p = 0.26) (Foster 
et al., 2003). Although this research showed that VLCD led to a greater weight loss during 3-6 
months, the longer study conducted over 12 months indicated that, compared to the traditional 
hypocaloric protocols, the VLCD diet provided no additional long-term advantages.  
Surprisingly, with regard to cardiovascular risk factors, according to the above studies, greater 
improvements were observed in people following the VLCD: triglycerides were significantly 
reduced, HDL cholesterol and sensitivity to insulin were increased, while the parameters of blood 
pressure and total lipids were unchanged. Apart from the specific composition of the diet, this 
result could have been due to the weight loss itself, which significantly improves the lipid profile 
and glucose tolerance. However, it must be remembered that these studies had some limitations, 
such as low adherence to the diet and high dropout rates.  
A few years later, Foster and colleagues performed another in vivo study, once again to compare 
LCD vs LFD, but this time the time was prolonged to 2 years of follow-up. The study was a 
randomized, controlled trial conducted with outcome assessments at baseline, 3, 6, 12 and 24 
months; participants were randomly assigned to LCD (153 subjects) or LFD (154 subjects). The 
results reported no differences in weight, body composition, or bone mineral density between the 
groups at any time point. As showed in previous studies, during the first 6 months, the LCD group 
had a greater reduction in diastolic blood pressure, triglyceride levels, and VLDL cholesterol levels, 
and a lower reduction in LDL cholesterol levels, than did the LFD group. However, in some 
variables already after 1 year, but especially at the end of the study (2 years) the differences in lipid 
profiles were no longer significant (Fig. 10). Therefore, the authors conclude that successful weight 
loss can be achieved with either LCD or LFD, without any particular cardiovascular disease risk 
factors at 2 years (Foster et al., 2010). 
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Fig. 10 Predicted absolute mean change in serum triglyceride, VLDL, LDL and HDL cholesterol concentrations 
in the low-fat and low-carbohydrate diet groups , * p <0.001, † p < 0.01 for between-group differences (Foster et 
al., 2010). 
There is an increasing necessity for longer studies, conducted both on overweight and large obese 
individuals, to evaluate weight loss effectiveness, with careful assessment of the energy balance and 
body composition, cardiovascular risk factors, diabetes, renal and skeletal health markers, without 
forgetting nutritional adequacy and quality of life. It is not known if moderately overweight people 
would have the same improvements in triglycerides and HDL-cholesterol, as demonstrated in 
obese participants of the studies, or if the levels of physical activity could change its effects. Thus, 
future studies should be undertaken for a sufficiently long time (at least 2 years) on different 
subjects to allow a careful monitoring of the above mentioned risk factors. 
1.4 KETOGENIC DIET & MICROBIOTA 
1.4.1 Role of microbiota 
In recent decades several studies have highlighted the key role of the microbiota in maintaining a 
correct status of host’s health (Rooks et al., 2014). The "microbiota" is defined as the entire 
population of microorganisms residing in different districts of the human organism. The intestinal 
population consists mainly of over 1000 different bacterial species, reaching 1014 microbial cells. 
Instead, if we consider the microbiome, which is the number of genes present in all the genomes of 
these microbial cells, it is 200 times larger than the number of genes of the entire human genome. 
Microbial density reaches its maximum levels in the distal portion of the colon, with a 
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concentration of about 1011 bacteria/gram of enteric content, while a smaller portion is represented 
by viruses, fungi and Archaea (Ley et al., 2006). 
Most of the microbiota in the gastrointestinal tract consist of anaerobic bacteria and, although more 
than 50 bacterial phyla have been described, human microbial communities are overwhelmingly 
dominated by: Bacteroidetes, Firmicutes, Actinobacteria, Proteobacteria and Verrycomicrobia (Fig. 11).  
The first two phyla make up over 90% of the colon community (Dethlefsen et al., 2007), and 
Firmicutes, Gram positive bacteria, are very active from the fermentation point of view: the 
metabolism of undigested food components determines the formation of short-chain fatty acids 
(SCFA), particularly butyrate (Pryde et al., 2002). Bacteroidetes, Gram negative bacteria, are 
associated with numerous beneficial effects, due to their ability to digest polysaccharides and 
proteins, especially producing acetate and propionate (Macfarlane & Macfarlane, 2003).  
  
Fig. 11 Predominant species of the human colonic micrbiota (Chassard & Lacroix, 2013). 
The microbiota performs various functions able to contribute in a concrete way to the state of 
health of the host, exerting a protective, structural and metabolic role (Fig. 12). The microbiota 
competes with pathogenic bacteria, producing substances capable of inactivating them, altering the 
intestinal pH, subtracting the nutrients and maintaining the integrity of the mucosal barrier. The 
mucosa is an important defence system against potentially immunogenic or pathogenic factors, 
food residues and organic secretions (Prakash et al., 2001). It also helps to preserve intestinal 
homeostasis, keeping cell junctions intact, and acts as a stimulus for the development and 
regulation of the immune system. The mucosa promotes the correct localization and response of 
Toll-Like Receptors (TLRs), key elements in the response to possible pathogens. The intracellular 
signal downstream of the TLRs induces the production of cytokines able to coordinate the 
inflammatory and immune response (Pessi et al., 2000). At metabolic level, the microbiota plays an 
important role in the synthesis of vitamins, such as vitamins K, B9 and B12. However, the main 
metabolic activity carried out by the intestinal microbiota is the fermentation of undigested 
substrates introduced with the diet, contributing to a large extent to energy recovery for the host, 
producing secondary metabolites, in particular SCFA (Wong et al., 2006). 
18 
 
 
Fig. 12 Main functions of microbiota (Prakash et al., 2011). 
1.4.1.1 Short chain fatty acids 
The colonic microbiota is able to ferment organic material that cannot be digested by the host in the 
upper gut, as humans lack the enzymes to degrade the bulk of dietary fiber. Fermentation results 
in multiple groups of metabolites of which SCFA are the major product. They are a class of 
saturated fatty acids characterized by an aliphatic chain length of less than 6 carbon atoms. Acetate 
(C2), propionate (C3) and butyrate (C4) are the most abundant, as they rapresent 90-95% of SCFA 
in the colon. Generally, the molar ratio acetate: propionate: butyrate is 60:20:20 and remains 
constant across the different regions of the colon, although absolute concentrations may vary 
(Macfarlane et al., 1992). Depending on the diet, the total concentration of SCFA ranges from 70 to 
140 mM in the proximal colon and from 20 to 70 mM in the distal colon (Topping & Clifton, 2000). 
The formation of SCFA by intestinal bacteria is affected by numerous factors including the source 
and the amount of substrate available, the bacterial species composition of the microbiota, the 
intestinal transit time and ecological factors such as cooperative interactions between different 
groups of bacteria (Huazano-Garcìa & Lòpez, 2013). Absorption of SCFA in the colon is rapid and 
reaches 95% (Donohoe et al., 2011), predominantly through apical carriers, such as the 
monocarboxylate-1 transporter and the sodium-coupled monocarboxylate-1 present in epithelial 
cells (Goncalves & Martel, 2013). This help promote the absorption of Na+, to maintain the base 
acid balance and energy homeostasis in the colonocytes, providing 5-10% of the total energy need 
(McNeil, 1984). Once absorbed by enterocytes, most SCFA are metabolized into lipids (Bergman, 
1990 – Zambell et al., 2003), resulting in a significant decrease in their concentration. SCFA that 
reach the liver are metabolized into lipids and small amounts are present in the peripheral blood 
(Bergman, 1990). 
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The main fermentable substrates in the intestine are the components of the dietary fiber, 
particularly the soluble fraction (Flint et al., 2008), such as "resistant" starch, non-starch 
polysaccharides, oligosaccharides and non-digestible sugars. Carbohydrate fermentation occurs 
through various biochemical reactions, among which the most important are glycolysis, for sugars 
with 6 carbon atoms, and the pentose-phosphate pathway, for sugars with 5 carbon atoms. The 
former is mainly used by Lactobacilli and Bacteroides, so that, after glucose phosphorylation, sugar is 
converted to pyruvate, a molecule that acts as an intermediate key for subsequent metabolic 
interactions with SCFA production. The second is the pentose-phosphate pathway used by bacteria 
belonging to the family Bacillaceae, Enterobacteriaceae and Enterococcaceae, in which the 
monosaccharides are converted into phosphoenolpyruvate (PEP). Subsequently the PEP is 
converted into fermentation products such as organic acids or alcohols (Miller & Wolin, 1996). 
Furthermore, the anaerobic metabolism of peptides and proteins at the colon level, by the bacteria, 
leads to the production of branched SCFAs (Branched Chain Fatty Acids, BCFA): isobutyrate, 
isovalerate and 2-methyl-butyrate, deriving specifically from the catabolism of the valine amino 
acids, leucine and isoleucine (Cummings & Englyst, 1987). 
SCFA are the main source of energy for enterocytes, thus any deficiency can determine the atrophy 
of the colonic mucosa. The colonic epithelium gets 60-70% of its energy from bacterial fermentation 
products, especially from butyrate (Cummings & Macfarlane, 1997), preferring it to acetate and 
propionate, but also to glucose. Several studies have shown how propionate and acetate can 
modulate the glyco-lipid metabolism, inhibiting the hepatic synthesis of cholesterol (propionate) 
(Demignè et al., 1995) and improving insulin sensitivity (acetate) (Brighenti et al., 1995). 
Furthermore, acetate also acts as a substrate for the synthesis of long chain fatty acids and as a 
co-substrate for the synthesis of glutamine and glutamate, while propionate acts as a precursor of 
gluconeogenesis in the liver (Roy et al., 2006). Butyrate is also able to modulate the gene expression 
by reducing the risk of formation of epithelial neoplastic cells in the colon. In vitro studies have 
shown the ability of butyrate to inhibit growth or promote the differentiation of human cells and 
induce apoptosis in tumor cells (Hague et al., 1995). It also seems to prolong the time of cell 
division and slow down the growth rate of colon-rectal tumor cell lines. Csordas (1996) associates 
this property of butyrate to the inhibition of histone deacetylase activity (HDACs) in enterocytes 
and immune cells. 
The production of SCFA affects the gut environment, primarily by decreasing pH, as large 
amounts of acids are produced. The initial pH drop prevents the growth of pH-sensitive 
pathogenic bacteria, such as some belonging to Enterobacteriaceae and Clostridia (Duncan et al., 
2009). At pH 5.5, butyrate-producing bacteria, for example Roseburia and Faecalibacterium 
prausnitzii, account for 20% of the total population, while in the most distal parts, where there is a 
lack of fermentable food fibers, the pH increases to 6.5. The butyrate-producing bacteria disappear 
almost completely and the bacteria associated with the Bacteroides, producers of acetate and 
propionate, become dominant (Walker et al., 2005). In addition, thanks to the intestinal pH 
reduction, SCFA contribute to the absorption of sodium, magnesium, vitamins and water at the 
colon, where they exert an anti-inflammatory action (Roberfroid, 2005). Butyrate inhibits the 
activation of the transcription factor NF-kB and consequently the production of pro-inflammatory 
cytokines (Segain et al., 2000; Luhrs et al., 2001). Overall, the various SCFA and the drop in pH 
induce colonic and systemic health effects (Fig. 13) (Chassard & Lacroix, 2013). 
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Fig. 13 General events taking place in the large intestine; prebiotics are fermented by bacteria to produce 
SCFA to improve host health (Huazano-Garcìa & Lopez, 2013). 
1.4.2 Microbiota & diet 
The association between microbiota and host is the result of numerous evolutionary processes, 
which have favoured the generation of a mutual beneficial condition for both the bacteria and for 
the host. When there is an altered composition of the intestinal ecosystem, a state called gut 
dysbiosis, physiological changes in the intestinal environment occur, disrupting the functions of 
the gut microbiota. Changes at the level of the microbial ecosystem have been indicated as crucial 
for the development of many diseases such as diabetes, obesity, inflammatory diseases, metabolic 
syndrome and also for some neurodegenerative and neurological diseases (Prakash et al., 2011). 
It has been clearly demonstrated that the human intestinal microbiota can be modulated by 
multiple elements, both genetic and environmental factors which can influence the inter-individual 
diversity of gut microbiota. Among environmental ones, the role of diet on the composition of gut 
microbiota is definitely one of the most important (Albenberg & Wu, 2014- Bibbò et al., 2016 - 
David et al., 2014 - Gong & Yang, 2012). Indeed, diet can impact not only the host directly, but can 
also have an indirect effect through the intestinal microbiota. The composition and duration of diet 
can affect bacteria but also viruses, Archaea, and fungi. In addition to the composition of the 
intestinal microbiota, diet affects its production of metabolites, which can influence host 
physiology (Fig. 14) (Albenberg & Wu, 2014).  
Alterations in the intestinal microbial population have been associated primarily with the 
consumption of dietary fiber from fruit and vegetables. In controlled trials in humans, variations in 
the intake of resistant starch and non-starch polysaccharides have shown the ability to modulate 
specific bacterial species such as Rominococcus bromii and Eubacterium rectale. It has been observed, 
by in vitro analysis on human faecal samples, that these taxa are able to metabolize specific 
substrates derived from soluble carbohydrate (Walker et al., 2011). Furthermore, animal models 
have shown the important capacity of the intestinal microbiota to metabolize glycans, deriving not 
only from the diet, but also from the mucus produced by the host. In fact, some microorganisms 
are able to modify their metabolism in relation to the availability of the substrates (Sonnenburg et 
al., 2005). 
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Fig. 14 Interactions among diet, the intestinal microbiota, and the host (Albenberg & Wu, 2014) 
Moreover, a diet low in carbohydrates and rich in proteins alters the colon microbiota, favoring a 
potentially pathogenic and pro-inflammatory microbial profile, a decreased production of SCFA 
and an increased concentration of ammonia, phenols and sulfuric acid (Guarner & Malagelada, 
2003). These metabolites largely compromise the structure of the colonic epithelium, causing 
inflammation of the mucosa, and can also interfere with the modulation of the enteric nervous 
system and intestinal motility. These factors can be of clinical importance in the approach to 
problems in which protein fermentation could be involved such as irritable bowel syndrome, 
inflammatory bowel disease and colorectal cancer prevention (Hugenholtza et al., 2013). 
The diet seems to influence the intestinal microbiota by interacting at various levels on human 
physiopathology. For instance, a diet rich in fiber stimulates the production of SCFA; instead, diets 
rich in red meat have been associated with an increased risk of colon cancer development as they 
could promote the production of sulfate-reducing bacteria producing hydrogen sulfide, a 
genotoxic agent (Albenberg & Wu, 2014). 
One of the most relevant studies in this field, which demonstrated the impact of diet in shaping gut 
microbiota, was published by De Filippo and collegues. They analyzed the gut microbiota of 
children aged 1-6 years old living in a rural village of Africa, specifically in Burkina Faso, and of 
Italian children living in Florence, in order to compare the environment typical of industrialized 
Europe with an environment close to that of Neolithic farmers. African children showed a 
significant enrichment in Bacteroidetes and depletion in Firmicutes with a unique abundance of 
Prevotella and Xylanibacter, completely lacking in Italian children. This result was consistent with 
a high abundance of SCFA and a lower level of Enterobacteriaceae in children from Burkina Faso 
compared to the Europeans. These results suggest that diet has a dominant role over other possible 
variables such as ethnicity, sanitation, hygiene, geography, and climate, in shaping the gut 
microbiota. The authors hypothesized that the reduction in microbial richness observed in 
Europeans compared with Burkina Faso children could indicate how the consumption of sugar, 
animal fat, and calorie-dense foods in industrialized countries is rapidly limiting the adaptive 
potential of the microbiota (De Filippo et al., 2010). 
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Diets greatly different from conventional ones, such as those with a low carbohydrate intake (e.g. 
KD, VLCD), are assumed to exhibit a very pronounced effect on the microbiota (David et al., 2014). 
Indeed, it has been shown, in animal model, that the consumption of a high fat diet is associated 
with large alterations in microbiota including a decrease in Bacteroidetes and an increase in both 
Firmicutes and Proteobacteria (Devkota et al., 2012 - Hildebrandt et al., 2009). However, very few 
studies have investigated the specific effect of a KD on the microbiota and they have been 
published only just recently. One of these is a pilot study perfomed on six patients affected by 
GLUT1-DS treated with KD. Fecal samples were collected and analysed before and after three 
months on the diet to evaluate any changes in the microbiota. Although at the phylum level there 
were no statistically significant differences at 3 months compared to baseline, Desulfovibrio spp. 
increased significantly. This bacterial group is supposed to be involved in the exacerbation of the 
inflammatory condition of the gut mucosa associated with the consumption of fats of animal 
origin. The authors concluded, considering the dysbiosis demonstrated by fecal samples, that a 
trial of pre- or pro-biotics could be suggested to potentially restore the correct balance of intestinal 
microbiota (Tagliabue et al., 2017). Another study, performed by Swidsinski and collegues, 
investigate once again the effect of KD on gut microbiota, but this time considering 10 patients 
affected by auto-immune multiple sclerosis (MS) using the diet for 6 months. They found that the 
total concentrations and diversity of substantial bacterial groups were reduced in MS patients. In 
particular, the results showed that some bacterial groups including Roseburia, Bacteroides and 
Faecalibacterium prausnitzii were diminished the most. Morevoer, the effects of a KD were biphasic. 
In fact, in the short term, the bacterial concentrations and diversity were further reduced, then at 
week 12 started to recover, and finally after 23-24 weeks significantly exceeded the baseline values. 
In summary, it seems that the KD can normalized concentrations of the colonic microbiome after 6 
months in MS patients (Swidsinski et al., 2017). Nevertheless, both studies were performed with a 
very small number of subjects, therefore more research is needed on this topic to better understand 
the role of KD on human gut in different contexts. 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
1.5 REFERENCES 
Abramovici S.; Bagić A. Epidemiology of epilepsy. Handb Clin Neurol, 2016, 138, 159-71. 
Albenberg L.G.; Wu G.D. Diet and the intestinal microbiome: associations, functions, and 
implications for health and disease. Gastroenterology, 2014, 146, 1564-1572. 
Astrup. A.; Larsen, T.M.; Harper, A. Atkins and other low-carbohydrate diets: Hoax or an effective 
tool for weight loss? Lancet, 2004, 364, 897–899. 
Atkins R.D.C. Dr. Atkins' New Diet Revolution, Government Institutes, 2002. 
Awaad Y.W,; Berry I.R.; Tomoum H.Y.; Elsayed S. M.; A novel frameshift mutation in SLC2A1 
associated with a mild form of glucose transporter type 1-related movement disorder. J Pediatr 
Neurol, 2015, 13(02), 088-091. 
Barañano K.W.; Hartman A.L. The ketogenic diet: uses in epilepsy and other neurologic illnesses. 
Curr Treat Options Neurol, 2008, 10(6), 410–419. 
Bergman E.N. Energy contributions of volatile fatty acids from the gastrointestinal tract in various 
species. Physiol Rev, 1990, 70, 567-590. 
Bergqvist C.; Schall J.I.; Stallings V.A.; Zemel B.S. Progressive bone mineral content loss in children 
with intractable epilepsy treated with the ketogenic diet. Am J Clin Nut, 2008, 88, 1678-1684. 
Bibbò S.; Ianiro G.; Giorgio V.; Scaldaferri F.; Masucci L.; Gasbarrini A.; Cammarota G. The role of 
diet on gut microbiota composition. Eur Rev Med Pharmacol Sci, 2016, 20(22), 4742-4749. 
Bough K.J.; Wetherington J.; Hassel B.; Pare J.F.; Gawryluk J.W.; Greene J.G.; Shaw R.; Smith Y.; 
Geiger J.D.; Dingledine R.J. Mitochondrial biogenesis in the anticonvulsant mechanism of the 
ketogenic diet. Ann Neurol, 2006, 60, 223-235. 
Brehm B.J.; Seeley R.J.; Daniels S.R.; D’Alessio D.A. A randomized trial comparing a very low 
carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk 
factors in healthy women. J Clin Endocrinol Metab, 2003, 88(4), 1617–1623. 
Brighenti F.; Castellani G.; Benini L.; Casiraghi M.C.; Leopardi E.; Crovetti R.; Testolin G. Effect of 
neutralized and native vinegar on blood glucose and acetate responses to a mixed meal in healthy 
subjects. Eur J Clin Nutr, 1995, 49, 242-7. 
Cahill Jr G.F. Fuel metabolism in starvation. Annu Rev Nutr, 2006, 80, 519-26. 
Cai Q.; Zhou Z.J.;, Luo R.; Gan J.; Li S.P.; Mu D.Z.; Wan C.M. Safety and tolerability of the ketogenic 
diet used for the treatment of refractory childhood epilepsy: a systematic review of published 
prospective studies. World J Pediatr, 2017, 13(6), 528-536. 
Caminhotto R.de O.; da Fonseca F.L.; de Castro N.C.; Arantes J.P.; Sertié R.A. Atkins diet program 
rapidly decreases atherogenic index of plasma in trained adapted overweight men. Arc Endocrinol 
Metab, 2015, 59-6, 568–71. 
Campbell M.K.; Farrell S.O. Biochimica, EDISES, 2012. 
24 
 
Caraballo R.H.; Cersósimo R.O.; Sakr D.; Cresta A.; Escobal N.; Fejerman N. Ketogenic diet in 
patients with myoclonic-astatic epilepsy. Epileptic Disorders, 2006, 8(2), 151-155. 
Chassard C.; Lacroix C. Carbohydrates and the human gut microbiota. Curr Opin Clin Nutr Metab 
Care, 2013, 16(4), 453-60. 
Chopra M.; Galbraith S.; Darnton-Hill I. A global response to a global problem: the epidemic of 
overnutrition. Bulletin of the World Health Organization, 2002, 80, 952-958. 
Csordas A. Butyrate, aspirin and colorectal cancer. Eur J Cancer Prevt, 1996, 5, 221-231. 
Cummings J.H.; Englyst H.N. Fermentation in the human large intestine and the available 
substrates. Clin Nutr, 1987, 45, 1243-1255. 
Cummings J.H.; Macfarlane G.T. Role of intestinal bacteria in nutrient metabolism. J Parent Ent Nutr, 
1997, 21, 357-365. 
David L.A.; Maurice C.F.; Carmody R.N.; Gootenberg D.B.; Button J.E.; Wolfe B.E.; Ling A.V.; 
Devlins A.S.; Varma Y.; Fischbach M.A.; Biddinger S.B.; Dutton R.J.; Turnbaugh P.J. Diet rapidly 
and reproducibly alters the human gut microbiome. Nature, 2014, 505, 559-563.   
De Giorgis V.; Teutonico F.; Cereda C.; Balottin U.; Bianchi M.; Giordano L.; Olivotto S.; Ragona F.; 
Tagliabue A.; Zorzi G.; Nardocci N.; Veggiotti P. Sporadic and familial GLUT1 DS Italian patients: a 
wide clinical variability. Seizure, 2015, 24, 28-32.     
De Filippo C.; Cavalieri D.; Di Paola M.; Ramazzotti M.; Poullet J.B.; Massart S.; Collini S.; Pieraccini 
G.; Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children 
from Europe and rural Africa. Proc Natl Acad Sci U.S.A., 2010, 107, 14691–14696.                                                         
De Vivo D.C.; Trifiletti R.R.; Jacobson R.I.; Ronen G.M.; Behmand R.A.; Harik S.I. Defective glucose 
transport across the blood—brain barrier as a cause of persistent hypoglycorrhachia, seizures, and 
developmental delay. N Engl J Med, 1991, 325(10), 703—709. 
Demigné C.; Morand C.; Levrat M.A.; Besson C.; Moundras C.; Rémésy C. Effect of propionate on 
fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Br J Nutr, 
1995, 74, 209-19. 
Dethlefsen L.; McFall-Ngai M.; Relman D.A. An ecological and evolutionary perspective on 
human-microbe mutualism and disease. Nature, 2007, 449(7164), 811-8. 
Devkota S.; Wang Y.; Musch M.W.; Leone V.; Fehlner-Peach H.; Nadimpalli A.; Antonopoulos D.A.; 
Jabri B.; Chang E.B. Dietary fat-induced taurocholic acid production promotes pathobiont and 
colitis in IL-10-/- mice. Nature, 2012, 487, 104-8. 
Donohoe D.R.; Garge N.; Zhang X.; Sun W.; O’Connell T.M.; Bunger M.K.; Bultman S.J. The 
microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell 
Metab, 2011, 13, 517-526. 
Dravet C. Les epilepsies graves de l’enfant. Vie Med, 1978, 8, 543–548. 
Dravet C. The core Dravet syndrome phenotype. Epilepsia, 2011, 52, 3-9. 
25 
 
Dressler A.; Trimmel-Schwahofer P.; Reithofer E.; Mühlebner A.; Gröppel G.; Reiter-Fink E.; 
Benninger F.; Grassl R.; Feucht M. Efficacy and tolerability of the ketogenic diet in Dravet syndrome 
- Comparison with various standard antiepileptic drug regimen. Epilepsy Res, 2015, 109, 81-9. 
Duncan S.H.; Louis P.; Thomson J.M.; Flint H.J. The role of pH in determining the species 
composition of the human colonic microbiota. Environ Microbiol, 2009, 11, 2112-2122. 
Flint H.J.; Bayer E.A.; Rincon M.T.; Lamed R.; White B.A. Polysaccharide utilization by gut bacteria 
potential for new insights from genomic analysis. Nat Rev Microbiol, 2008, 6, 121-131. 
Foster G.D.; Wyatt H.R.; Hill J.O.; McGuckin B.G.; Brill C.; Mohammed S.B.; Szapary P.O.; Rader 
D.J.; Edman J.S.; Klein S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med, 
2003, 348, 2082-90. 
Foster G.D.; Wyatt H.R.; Hill J.O.; Makris A.P.; Rosenbaum D.L.; Brill C.; Stein R.I.; Mohammed B.S.; 
Miller B.; Rader D.J.; Zemel B.; Wadden T.A.; Tenhave T.; Newcomb C.W.; Klein S. Weight and 
metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann 
Intern Med, 2010, 153(3), 147–157. 
French J.A. Refractory epilepsy: clinical overview. Epilepsia, 2007, 48, 3-7. 
Freeman, J.M.; Vining, E.P.G.; Pillas, D.J.; Pyzik, P.L.; Casey, J.C.; Kelly, M.T. The efficacy of the 
ketogenic diet—1998: A prospective evaluation of intervention in 150 children. Pediatrics, 1998, 102, 
1358–1363. 
Frommelt L., Bielohuby M., Stoehr B. J. M., Menhofer D., Bidlingmaier M., Kienzle E., Effects of 
low-carbohydrate, high-fat diets on apparent digestibility of minerals and trace elements in rats. 
Nutrition, 2014, 30, 869–875. 
Fukao, T.; Lopaschuk, G.D.; Mitchell, G.A. Pathways and control of ketone body metabolism: On 
the fringe of lipid biochemistry. Prostag Leukotr Ess, 2004, 70, 243–251. 
Furth S.L.; Casey J.C.; Pyzik P.L.; Neu A.M.; Docimo S.G.; Vining E.P.G.; Freeman J.M.; Fivush B.A. 
Risk factors for urolithiasis in children on the ketogenic diet. Pediatr Nephrol, 2000, 15, 125–128. 
Giacco F.; Brownlee M. Oxidative stress and diabetic complications. Circ Res, 2010, 107, 1058–70. 
Gonçalves P.; Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Curr Drug 
Metab, 2013, 14, 994-1008. 
Gong J.; Yang C. Advances in the methods for studying gut microbiota and their relevance to the 
research of dietary fiber functions. Food Res Int, 2012, 48, 916-929. 
Groesbeck D.K.; Bluml R.M.; Kossoff E.M. Long-term use of the ketogenic diet in the treatment of 
epilepsy. Dev Med Child Neurol, 2006, 48, 978–981. 
Guarner F.; Malagelada J.R. Gut flora in health and disease. Lancet, 2003, 361, 512-529. 
Hague A.; Elder D.J.E.; Hicks D.J.; Paraskeva A.C. Apoptosis in colorectal tumour cells: induction 
by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J 
Cancer, 1995, 60, 400-406. 
Hartman A.L.; Vining, E.P.G. Clinical aspects of the ketogenic diet. Epilepsia, 2007, 48-1, 31–42. 
26 
 
Hildebrandt M.A.; Hoffman C.; Sherrill-Mix S.A.; Keilbaugh S.A.; Hamady M.; Chen Y.; Knight R.; 
Ahima R.S.; Bushman F.; Wu G.D. High fat diet determines the composition of the murine gut 
microbiome independently of obesity. Gastroenterology, 2009, 137, 1716 e24. 
Huazano-Garcia A.; Lòpez M.G. Metabolism of short chain fatty acids in the colon and faeces of 
mice after a supplementation of diets with agave fructans. Lipid Metabolism, 2013, 8, 163-182. 
Hugenholtza F.; Mullaneyd J.A.; Kleerebezemb M.; Smidta H.; Rosendale D. Modulation of the 
microbial fermentation in the gut by fermentable carbohydrates. Bioact Carbohydr Dietary Fibre, 2013, 
2, 133-142. 
Jabre M.G.; Bejjani B.P. Treatment of Parkinson disease with diet-induced hyperketonemia: a 
feasibility study. Neurology, 2006, 66(4), 617. 
Kang H.C.; Chung D.E.; Kim D.W.; Kim H.D. Early- and late-onset complications of the ketogenic 
diet for intractable epilepsy. Epilepsia, 2004, 45(9), 1116–1123. 
Kashiwaya, Y.; Bergman, C.; Lee, J.H.; Wan, R.; King, M.T.; Mughal, R.M.; Okun, E.; Clarke, K.; 
Mattson, M.P.; Veech, R.L. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, 
and lessens amyloid and tau pathologies in a mouse model of Alzheimer’s disease. Neurobiol Aging, 
2013, 34-6, 1530–1539. 
Khodadadi S.; Sobhani N.; Mirshekar S.; Ghiasvand R.; Pourmasoumi M.; Miraghajani M.; 
Dehsoukhteh S.S. Tumor cells growth and survival time with the ketogenic diet in animal models: a 
systematic review. Int J Prev Med, 2017, 8, 35. 
Kim D.Y.; Rho J.M. The ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care, 2008, 11, 
113–20. 
King D.E.; Mainous A.G.; Carnemolla M.; Everett C. J. Adherence to healthy lifestyle habits in US 
adults, 1988-2006. Am J Med, 2009, 122, 528-534. 
Klement RJ1. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on 
evidence and confirmation. Med Oncol, 2017, 34(8), 132. 
Klepper J. Glucose transporter deficiency syndrome (GLUT1DS) and the ketogenic diet. Epilepsia, 
2008, 49, 46-9. 
Kossoff E.H.; Pyzik P.L.; Furth S.L.; Hladky H.D.; Freeman J. M.; Vining E.P.G. Kidney stones, 
carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia, 2002, 43(10), 1168–1171. 
Kossoff E.H.; Pyzik P.L.; McGrogan J.R.; Rubenstein J.E. The impact of early versus late 
anticonvulsant reduction after ketogenic diet initiation. Epilepsy Behav, 2004, 5, 499–502. 
Kossoff E.H.; McGrogan J.R. Worldwide use of the koetogenic diet, Epilepsia, 2005, 46(2), 280-289. 
Kossoff E.H.; Rowley H.; Sinha S.R.; Vining E.P.G. A prospective study of the modified Atkins diet 
for intractable epilepsy in adults. Epilepsia, 2008, 49, 316–319. 
Kwan P.; Brodie M.J. Early identification of refractory epilepsy. N Engl J Med, 2000, 342(5), 314-9. 
Laffel L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to 
diabetes. Diabetes Metab Res Rev, 1999, 15-6, 412–426. 
27 
 
Larsen J.; Carvill G.L.; Gardella E.; Kluger G.; Schmiedel G.; Barisic N.; Depienne C.; Brilstra E.; 
Mang Y.; Nielsen J.E.; Kirkpatrick M.; Goudie D.; Goldman R.; Jähn J.A.; Jepsen B.; Gill D.; Döcker 
M.; Biskup S.; McMahon J.M.; Koeleman B.; Harris M.; Braun K.; de Kovel C.G.; Marini C.; Specchio 
N.; Djémié T.; Weckhuysen S.; Tommerup N.; Troncoso M.; Troncoso L.; Bevot A.; Wolff M.; 
Hjalgrim H.; Guerrini R.; Scheffer I.E.; Mefford H.C.; Møller R.S. The phenotypic spectrum of 
SCN8A encephalopathy. Neurology, 2015, 84(5), 480-9.  
Lee R.W.Y.; Corley M.J.; Pang A.; Arakaki G.; Abbott L.; Nishimoto M.; Miyamoto R.; Lee E.; 
Yamamoto S.; Maunakea A.K.; Lum-Jones A.; Wong M. A modified ketogenic gluten-free diet with 
MCT improves behavior in children with autism spectrum disorder. Physiol Behav, 2018, 188, 
205-211. 
Ley R.E.; Peterson D.A.; Gordon J.I. Ecological and evolutionary forces shaping microbial diversity 
in the human intestine. Cell, 2006, 124, 837-848. 
Liu Y.C.; Williams S.; Basualdo-Hammond C.; Stephens D.; Curtis R. A prospective study: Growth 
and nutritional status of children treated with the ketogenic diet. J Am Diet Assoc, 2003, 103, 707-712. 
Luhrs H.; Gerke T.; Schauber J.; Dusel G.; Scheppach W.; Menzel T. Cytokine-activated degradation 
of inhibitory kB protein alpha is inhibited by the short chain fatty acid butyrate. Int J Colorect Dis, 
2001, 16,  195-201. 
Ma W.; Berg J.; Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening 
K(ATP) channels. J Neurosci, 2007, 27, 3618-3625. 
Macfarlane G.T.; Gibson G.R.; Cummings J.H. Comparison of fermentation reactions in different 
regions of the human colon. Appl Bactreriol, 1992, 72, 57-64. 
Macfarlane S.; Macfarlane G.T. Regulation of short-chain fatty acid production. Proc Nutr Soc,  
2003, 62(1), 67-72. 
Malvezzi M.; Bertuccio P.; Levi F.; La Vecchia C.; Negri E. European cancer mortality predictions for 
the year 2013. Ann Oncol, 2013, 24, 792–800. 
McNeil N. The contribution of the large intestine to energy supplies in man. Clin Nutr, 1984, 39, 
338-342. 
Michael-Titus A.T.; Priestley J.V. Omega-3 fatty acids and traumatic neurological injury: from 
neuroprotection to neuroplasticity? Trends Neurosci, 2014, 37(1), 30-8. 
Mihaylova M.M.; Shaw R.J. Metabolic reprogramming by class I and II histone deacetylases. Trends 
Endocrinol Metab, 2013, 24, 48–57. 
Miller T.L.; Wolin M.J. Pathways of acetate, propionate, and butyrate formation by the human fecal 
microbial flora. Appl Environ Microbiol, 1996, 62, 1589–1592. 
Muzykewicz D.A.; Lyczkowski D.A.; Memon N.; Conant K.D.; Pfeifer H.H.; Thiele E.A. Efficacy, 
safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. Epilepsia, 2009, 
50(5), 1118-26. 
Napoli E.; Dueñas N.; Giulivi C. Potential therapeutic use of the ketogenic diet in autism spectrum 
disorders. Front Pediat, 2014, 2(69). 
28 
 
Neal E.G.; Chaffe H.; Schwartz R.H.; Lawson M.S.; Edwards N.; Fitzsimmons G.; Whitney A.; Cross 
J.H. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment 
of childhood epilepsy. Epilepsia, 2009, 50(5), 1109-17.  
Nehlig, A. Brain uptake and metabolism of ketone bodies in animal models. Prostag Leukotr Ess, 
2004, 70(3), 265–75. 
Newman J.C.; Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab, 2014, 25(1), 
42-52. 
Noh H.S.; Hah Y.S.; Nilufar R.; Han J.; Bong J.; Kang S.S.; Cho G.J.; Choi W.S.; Acetoacetate protects 
neuronal cells from oxidative glutamate toxicity. J Neurosci Res, 2006, 83, 702–709. 
Patel K.P.; O’Brien T.W.; Subramony S.H.; Shuster J.; Stacpoole P.W. The spectrum of pyruvate 
dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol 
Genet Metab, 2012, 106(3), 385–394. 
Pessi T.; Sütas Y.; Hurme M.; Isolauri E. Interleukin-10 generation in atopic children following oral 
Lactobacillus rhamnosus GG. Clin Exp Allergy, 2000, 30, 1804-1808. 
Pezzana A.; Amerio M.L.; Fatati G.; Caregaro N.L.; Muratori G.; Rovera G.; Zanardi M. La dieta 
chetogenica. Fondazione ADI: position paper 2014, 6, 38-43. 
Pfeifer H.H.; Thiele E.A. Low glycemic index treatment: a liberalized ketogenic diet for treatment of 
intractable epilepsy. Neurology, 2005, 65, 1810–1812. 
Prakash S.; Rodes L.; Coussa-Charley M.; Tomaro-Duchesneau C. Gut microbiota: next frontier in 
understanding human health and development of biotherapeutics. Biologics, 2011, 5, 71-86. 
Pryde S.E.; Duncan S.H.; Hold G.L.; Stewart C.S.; Flint H.J. The microbiology of butyrate formation 
in the human colon. FEMS Microbiol Lett, 2002, 217(2), 133-9. 
Roberfroid M.B. Introducing inulin-type fructans. Brit J Nutr, 2005, 93, 13S- 25S. 
Rooks M.G.; Veiga P.; Wardwell-Scott L.H.; Tickle T.; Segata N.; Michaud M.; Gallini C.A.; Beal C.; 
Van hylckama-Vileg J.E.; Ballal S.A.; Morgan X.C.; Glickman J.N.; Gevers D.; Huttenhower C.; 
Garret W.S. Gut microbiome composition and function in experimental colitis during active disease 
and treatment-induced remission. ISME J, 2014, 8, 1403-1417. 
Roy C.C.; Kien C.L.; Bouthillier L.; Levy E. Short chain fatty acids: ready for prime time? Nutr Clin 
Pract, 2006, 21, 351–366. 
Rho JM1. How does the ketogenic diet induce anti-seizure effects? Neurosci Lett, 2017, 637, 4-10. 
Samaha F.F.; Iqbal N.; Seshadri P.; Chicano K.L.; Daily D.A.; McGrory J.; Williams T.; Williams M.; 
Gracely E.J.; Stren L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J 
Med, 2003, 348, 2074-2081. 
Segain J.P.; delaBletiere D.R.; Boureille A.; Leray V.; Gervois N.; Rosales C.; Ferrier L.; Bonnet C.; 
Blottiere H.M.; Glamiche J.P. Butyrate inhibits inflammatory responses through NFkB inhibition: 
implications for Crohn’s disease. Gut, 2000, 47, 397-403. 
29 
 
Seyfried T.N.; Flores R.E.; Poff A.M.; D’Agostino D.P. Cancer as a metabolic disease: Implications 
for novel therapeutics. Carcinogenesis, 2014, 35, 515-27. 
Sofou K.; Dahlin M.; Hallböök T.; Lindefeldt M.; Viggedal G.; Darin N. Ketogenic diet in pyruvate 
dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis, 2017, 40, 
237–245. 
Sonnenburg J.L.; Xu J.; Leip D.D. Glycan foraging in vivo by an intestine adapted bacterial 
symbiont. Science, 2005, 307, 1955-1959. 
Steel D.; Symonds J.D.; Zuberi S.M.; Brunklaus A. Dravet syndrome and its mimics: beyond SCN1A. 
Epilepsia, 2017, 58(11), 1807-1816. 
Swidsinski A.; Dörffel Y.; Loening-Baucke V.; Gille C.; Göktas Ö.; Reißhauer A.; Neuhaus J.; 
Weylandt K.H.;, Guschin A.; Bock M. Reduced mass and diversity of the colonic microbiome in 
patients with multiple sclerosis and their improvement with ketogenic diet. Front Microbiol, 2017, 8, 
1141. 
Tagliabue A.; Ferraris C.; Uggeri F.; Trentani C.; Bertoli S.; de Giorgis V.; Veggiotti P.; Elli M. 
Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 
3-month prospective observational study. Clin Nutr ESPEN, 2017, 17, 33-37. 
Tamosiunas A.; Luksiene D.; Baceviciene M.; Bernotiene G.; Radisauskas R.; Malinauskiene V.; 
Butylkiniene D.; Virviciute D.; Peasey A.; Bobak M. Health factors and risk of all-cause, 
cardiovascular, and coronary heart disease mortality: findings from the MONICA and HAPIEE 
Studies in Lithuania. PLOS ONE, 2014, 9(12). 
Taylor M.K.; Debra K. Sullivan D.K.; Mahnken J.D.; Burn J.M.; Swerdlow R.H. Feasibility and 
efficacy data from a ketogenic diet intervention in Alzheimer's disease. Alzheimers Dement, 2018, 4, 
28-36. 
Topping D.L.; Clifton P.M. Short-chain fatty acids and human colonic function: roles of resistant 
starch and nonstarch polysaccharides. Physiol Rev, 2001, 81, 1031-1064 . 
Vanitallie T.B.; Nonas C.; Di Rocco A.; Boyar K.; Hyams K.; Heymsfield S.B. Treatment of Parkinson 
disease with diet-induced hyperketonemia: A feasibility study. Neurology, 2005, 64, 728–730.  
Veggiotti P.; De Giorgis V. Dietary treatments and new therapeutic perspective in GLUT1 
deficiency syndrome. Curr Treat Options Neurol, 2014, 16, 291. 
Walker A.W.; Duncan S.H.; McWilliam Leitch E.C.; Child M.W.; Flint H.J. pH and peptide supply 
can radically alter bacterial populations and short-chain fatty acid ratios within microbial 
communities from the human colon. Appl Environ Microbiol, 2005, 71, 3692-3700. 
Walker A.W.; Ince J. Duncan S.H.; Webster L.M.; Holtrop G.; Ze X.; Brown D.; Stares M.D.; Scott P.; 
Bergerat A.; Louis P.; McIntosh F.; Johnstone A.M.; Lobley G.E.; Parkhill J.; Flint H.J.  Dominant 
and diet responsive groups of bacteria within the human colonic microbiota. Isme J, 2011, 5, 220-230. 
Wheless J.W. The ketogenic diet: an effective medical therapy with side effects. J Child Neurol, 2001, 
16, 633-635. 
Wild S.; Roglic G.; Green A.; Sicree R.; King H. Global prevalence of diabetes estimates for the year 
2000 and projections for 2030. Diabetes Care, 2004, 27, 5. 
30 
 
Wilder R.M. The effect of ketogenemia on the course of epilepsy. Mayo Clin Bull, 1921, 2, 307–14. 
Wong J.M.; de SR Kendall C.W.; Emam A.; Jenkins D.J. Colonic health: fermentation and short chain 
fatty acids. J Clin Gastroenterol, 2006, 40, 235–243. 
Yang X.; Cheng B. Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP 
induced neurotoxicity. J Mol Neurosci, 2010, 42, 145–153. 
Yudkoff M.; Daikhin Y.; Nissim I.; Horyn O.; Lazarow A.; Luhovyy B.; Wehrli S.;  Nissim I. 
Response of brain amino acid metabolism to ketosis. Neurochem Int, 2005, 47, 119–128. 
Zambell K.L.; Fitch M.D.; Fleming S.E. Acetate and butyrate are the major substrates for de novo 
lipogenesis in rat colonic epithelial cells. Nutrition, 2003, 133, 3509-3515. 
Zupec-Kania  B.A.;  Spellman  E.  An  overview  of  the  ketogenic diet for pediatric epilepsy. 
Nutr Clin Pract, 2008, 23, 589–96. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
2 AIM OF THE STUDY 
The overall aim of the present Ph.D. thesis was to investigate the metabolic effects of KB and KD, 
through both in vitro and in vivo approaches. Thus, the research project has been subdivided in two 
part, as described below: 
 
PART I  
In the first part we focused our attention on the vascular risk represented by KD-induced oxidative 
stress. We evaluated the effects of physiological levels of KB by measuring markers of oxidative 
stress using an in vitro model of endothelium. With this aim, we decided to investigate: a) the DNA 
oxidative damage by comet assay in order to study the genotoxicity due to KB; b) the ability of KB to 
modulate DNA susceptibility toward a secondary oxidative insult and c) the cell adaptive metabolic 
response to KB exposure, by activation of the Nrf2, which is a transcriptional factor involved in the 
cellular response to a stress, by western blot, immunofluorescence and real time PCR. 
 
PART II 
The second part was devoted to verify the impact of the KD on human intestinal environment, by an 
in vivo study. This project was in collaboration with the Human Nutrition and Eating Disorder 
Research Center of the University of Pavia, where the subjects were recruited. After the collection of 
the samples, three different activities were scheduled: a) analysis of the composition of gut bacteria 
(NGS, qPCR) performed in collaboration with the Department of Health Sciences of Università degli 
Studi di Milano; b) assessment of markers of bacterial metabolism (SCFA) and c) evaluation of fecal 
water citotoxicity and genotoxicity (Trypan blue, Comet assay). 
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3 PART I: IN VITRO STUDY 
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3.1 MATERIALS & METHODS 
3.1.1 Cell culture 
For this in vitro study, we chose to use a cell line of human microvascular endothelial cells 
(HMEC-1) (Fig. 15). HMEC-1 are a long-term cell line immortalized by simian-virus-40 large T 
antigen, provided by the Center for Disease Control and Prevention, Atlanta, GA, USA. These cells 
have been reported to retain the morphologic, phenotypic and functional characteristics of normal 
human microvascular endothelial cells (Ades et al., 1992). Moreover, comparing different 
endothelial cell lines, HMEC-1 is considered the most suitable model to investigate microvascular 
endothelium (Bouïs et al., 2001).  
  
Fig. 15 HMEC-1 cells at low and high density (ATCC). 
HMEC-1 cells were cultivated in MCDB131 medium supplemented with 10% fetal bovine serum, 10 
ng/mL epidermal growth factor, 1 μg/mL hydrocortisone, 2 mM glutamine, 100 U/mL penicillin, 
100 μg/mL streptomycin and 20 mM HEPES buffer.  
The cells were cultured in a 75 cm2 flask and, before the cells reached the complete confluence 
(about 80%), a dilution of 1 to 4 was carried out every 3-4 days. In particular, when cells reached the 
sub-culturing density of 80% the medium was removed and cells were washed with PBS. Then the 
cells were supplemented with trypsin-EDTA solution and left in the incubator for few minutes, 
until their detachment. Trypsin action was arrested by addition of complete medium, cell 
suspension was centrifuged for 5 min at 350xg. After removing supernatant, cell pellet was 
re-suspended in complete medium and seeded at 4.5 × 103 cells/cm2.  
For the analysis, cells were seeded at a density of 5 × 104 cells/cm2 in 60 mm Petri dishes and allowed 
to reach confluence in 24 h; then, cells were supplemented with KB dispersed in complete medium, 
and incubated at 37 °C in an atmosphere containing 5% of CO2 , according to the experimental 
design. 
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3.1.2 Treatment with ketone bodies 
Stock solutions for AA (acetoacetic acid lithium - A8509; Sigma Chemical Co.) and βHB 
(β-hydroxybutyric acid – 298360; Sigma Chemical Co.) were prepared in sterilized water. HMEC-1 
cells were supplemented with different concentrations of KB: from 2 to 20 mM for βHB and from 0.5 
to 5 mM for AA. To simulate the physiological condition both βHB and AA were incorporated 
simultaneously in cell treatments in a ratio 4:1, which occurs in vivo after the induction of ketosis 
(Fukao et al., 2004). 
 
3.1.3 Cell viability 
Cell viability was determined by the MTT reduction assay (Fotakis & Timbrell, 2006). The test is 
based on the ability of the MTT compound (tetrazolium salt, 3- (4,5-dimethylthiazol-2-yl) 
-2,5-diphenyl-tetrazolium bromide) to be metabolized by a mitochondrial enzyme, succinate 
dehydrogenase. The reduction of MTT leads to the formation of blue crystals of formazan, which is 
insoluble in water. Vital cells, unlike non-viable cells, reduce MTT, so the amount of formazan 
produced is proportional to the number of live cells present. The procedure used in this study has 
been already described (Meroni et al., 2018). 
 
3.1.4 Comet assay 
The comet assay (Single Cell Gel Electrophoresis) is an in vitro assay of increasing use in toxicology, 
not only for testing the genotoxic potential of substances in vitro, but also for human bio-monitoring 
in vivo studies (Sasaki et al., 2000). It is used to quantify the breaking of single strands of DNA 
(corresponding to oxidized bases) and the formation of alkali labile sites, at the single cell level. This 
technique has been demonstrated in several studies to have excellent sensitivity in the 
determination even minimal levels of oxidative damage; moreover, it does not require an excessive 
number of cells and is simple to perform (Tice et al., 2000 – Erba et al., 2014). The procedure involves 
the incorporation of cells in agarose, their lysis, the passage of the lysate in alkaline buffer, which 
determines the complete unfolding of the nuclear DNA, the electrophoresis, the colouring phase 
and the processing of images acquired under a microscope (Fig. 16).  
DNA strands without breaks migrate poorly and tend to remain concentrated in a nucleoid, while 
fragments generated by strand breaks migrate in inverse proportion to their length and molecular 
weight. At the end of the electrophoretic migration, the cell lysate is coloured with ethidium 
bromide and visualized by fluorescence microscope: the sample assumes the appearance of a comet, 
with a tail that is longer and brighter the more DNA is fragmented (Tice et al., 2000). 
In this study, the Comet assay was used to evaluate the genotoxicity of KB exposure on HMEC-1. 
The experimental procedure was designed according to the criteria reported in literature (Erba et al., 
2014), applying appropriate modifications (Meroni et al., 2018). Particularly, based on the results of 
the viability test, cells were exposed to KB (βHB 4 mM, AA 1 mM) for 2, 24 and 48 h at 37 °C with 
95% humidity and 5% CO2. Every treatment was performed in triplicate; both negative (cells 
without KB) and positive (cells treated with H2O2: 50 μM for 5 min) controls were included in each 
batch. Among the stimuli used to produce quantifiable oxidative damage to DNA and modulated 
by the presence of antioxidants, hydrogen peroxide has proved to be the most effective and 
reproducible (Erba et al., 2003). 
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Fig. 16 Different steps of Comet assay. 
After incubation, an aliquot of cells was used for the trypan blue exclusion test in order to verify cell 
viability (Strober, 2001). Another aliquot of cells was centrifuged (11,000 g, for 15 s; SL16R Thermo 
Fisher Scientific), re-suspended in 1.5% low melting point agarose, and spread on a microscope 
slide previously covered with 1% normal melting point agarose. Embedded cells were lysed and 
electrophoresis was performed at 25 V and 300 mA for 20 min. The slides were then immersed in 
neutralization buffer, stained with ethidium bromide and analyzed using a fluorescence microscope 
(BX60 Olympus, Tokyo, Japan) equipped with Image-Pro Plus software (Immagini & Computer, 
Bareggio; Milano, Italy).  
In order to achieve realistic pictures of DNA damage it is necessary to randomly acquire from 50 to 
60 images per slide. The different luminescence represents the DNA of the individual cells. When 
the DNA is not damaged, it does not migrate during electrophoresis and forms rounded images 
(Fig. 17-A). Instead, the DNA fragments of a damaged cell migrate to the positive pole during 
electrophoresis. The image displayed in this case will be similar to a comet (Fig. 17-B), with a head 
(the brightest part) that represents the undamaged DNA and a tail formed by the fragments of the 
migrated DNA. The extent of DNA damage, in terms of breakage, is estimated by the acquisition of 
two parameters: percentage of DNA in the tail (measurable as fluorescence intensity after staining) 
and tail length. It is possible to calculate the “tail moment”, defined as the product of the relative 
fluorescence intensity of the tail due to its length, which is assumed as an index of DNA damage 
(Collins et al., 2001). For these reasons, in this study 50 images were analyzed for each slide and the 
tail moment was registered. 
 
Fig. 17 Example of less (A) and more (B) damaged DNA. 
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3.1.5 RNA extraction and gene expression 
Real-time reverse transcription quantitative PCR (RT-PCR) is the most versatile method for single 
cell mRNA analysis. It offers quantitative information about transcript levels, and it can be used for 
fast, accurate, sensitive and cost-effective gene expression analysis (Derveaux et al., 2010 - Kubista et 
al., 2006). In this study, total RNA was isolated with the RNeasy Mini Kit (Qiagen, Hilden, 
Germany), following the protocol suggested by the manufacturer. Then, 0.8 μg of RNA was 
reverse-transcribed employing the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA , 
USA). Real-Time PCR was performed using an iCycler thermal cycler (Bio-Rad Laboratories) with 
cDNA corresponding to 10 ng of total RNA as the template. The PCR mixture included 0.2 μM 
primers (sequences in Tab. 6) and 1X SYBR Green PCR Master Mix (Bio-Rad Laboratories) in a final 
volume of 20 μL. 
Genes Primer Sequences 
Nrf2 F: 5′-AGCACATCCAGTCAGAAACC-3′ R: 5′-TGAAACGTAGCCGAAGAAAC-3′ 
HO-1 F: 5′-CAACATCCAGCTCTTTGAGG-3′ R: 5′-AGAAAGCTGAGTGTAAGGAC-3′ 
GAPDH F: 5’-AGGGCTGCTTTTAACTCTGG-′ R: 5′-CATGGGTGGAATCATATTGG-3′ 
Tab. 6 List of primer used for real-time reverse transcription-polymerase chain reaction (RT-PCR). 
Amplification and real-time data acquisition were performed using the followed cycle conditions: 
initial denaturation at 95 °C for 3 min, followed by 45 cycles of 10 s at 95 °C and 30 s at 58 °C. The 
fold change in expression of the different genes in treated HMEC-1 cells compared with control cells 
was normalized to the expression of GAPDH and was calculated by the equation 2-∆∆Ct using iQ5 
software version 2.0 (Bio-Rad Laboratories, Hercules, CA , USA). All reactions were performed in 
triplicate, and the accuracy was monitored by analysis of the PCR product melting curve. 
3.1.6 Western blot analysis 
Western blotting is a technique that allows the identification of a protein within a sample by 
recognition by specific antibodies, after electrophoresis. The method is based on an electrophoretic 
separation such as SDS-PAGE, (Sodium dodecylsulphate-polyacrylamide gel electrophoresis, 
polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate), the transfer of the 
separated proteins on a support consisting of a nitrocellulose membrane or of PVDF and the 
detection of the bands of interest by incubation with specific antibodies. The technique allows not 
only to detect the presence of a target protein, but also an estimation of its relative level of 
expression. 
After treatment with KB, cell pellets were lysed with a buffer containing 10 mM HEPES pH 8.0, 1.5 
mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT), 0.05% Nonidet P-40 (NP-40), 1 mM Na3VO4 
and protease inhibitors. In order to isolate nuclear compartments, lysates were centrifuged at 2500 g 
at 4 °C for 10 min and the supernatants (cytoplasm extracts) were collected. Then, pellets were 
re-suspended in a lysis buffer with protease inhibitors, and nuclear extracts were clarified by 
centrifugation (10,000 g at 4 °C for 5 min) and collected in new tubes. The concentration of protein in 
the samples was measured by Bradford’s method (Bradford, 1976). 
Proteins were denatured by boiling for 5 min in sodium dodecylsulfate (SDS) sample buffer, loaded 
into 10% SDS-PAGE gels and subsequently transferred onto PVDF membranes by electroblotting. 
Then, the membranes were incubated in Tris-buffered Saline for 1 h. Blots were incubated with 
37 
 
primary antibodies in the appropriate blocking solution at 4 °C overnight. The following primary 
antibodies were used: Nrf2 (C-20, Santa Cruz Biotechnology, Inc., Dallas, TX, USA) dilution 1:400 in 
TBS-T+5% (w/v) non-fat dried milk; GAPDH (FL-335, Santa Cruz Biotechnology, Inc.) dilution 1:500 
in TBS-T+5% (w/v) non-fat dried milk; lamin A/C (N-18, Santa Cruz Biotechnology, Inc.) dilution 
1:500 in TBS-T+5% BSA. Membranes were washed three times for 10 min and then incubated with 
the appropriate secondary antibody conjugated with horseradish peroxidase for 1 h. For the 
immunological detection of proteins, the enhanced chemiluminescence system (Pierce 
Biotechnology, Waltham, MA, USA) was used. The acquisition of PVDF membrane images and the 
densitometric analysis of blots was performed using an Alliance MINI HD9 (UVItec) apparatus 
(Cleaver Scientific, Warwickshire, United Kingdom) and related software. 
3.1.7 Immunofluorescence staining 
Cells were preliminarily washed twice with PBS and fixed using a solution of 4% (w/v)  
paraformaldehyde in PBS for 10 min at room temperature. For permeabilization and blocking, cells 
were incubated with PBS + 1% (w/v) bovine serum albumin solution (BSA) and 0,2% (v/v) Triton 
X-100 for 30 min at room temperature. Cells were then incubated with anti-Nrf2 (C-20) rabbit 
polyclonal antibody (Santa Cruz Biotechnology) at dilution of 1:200 in blocking solution overnight 
at 4°C. After removing the primary antibody, cells where washed three times in blocking solution 
and incubated with the anti-rabbit FITC-conjugated secondary antibody at dilution of 1:100 in 
blocking solution for 1 h at room temperature in the dark. Cells were analyzed using a fluorescence 
microscope (IX50 Olympus) equipped with VarioCam acquisition camera and Image-Pro Plus 
software (Media Cybernetics).  
3.1.8 Statistical analysis  
Experimental results are expressed as mean ± S.D. of three (four for western blot) independent 
measurements. The data for various parameters were analyzed by one-way analysis of variance 
(ANOVA) with SPSS Statistics 22 (IBM). Tukey test was used to detect significant differences (p < 
0.001 for comet assay analysis, p < 0.05 for cell viability, western blot and PCR analysis). 
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3.2 RESULTS 
The results reported in this section have been recently published (Meroni et al. 2018). 
3.2.1 Cell viability 
Cells were treated with various concentrations of βHB and AA for different times (24, 48 and 72 h). 
Concentrations up to 4 mM βHB and 1 mM AA showed no significant effects on cell viability up to 
48 h (Fig. 18). Higher concentrations were harmful at 48 h, and lower concentrations were damaging 
at 72 h. Considering this outcome, and assuming that 48 h is an appropriate time to detect a 
metabolic cellular response to an external stimulus, all further investigations were performed on 
HMEC-1 cells exposed to 4 mM βHB and 1 mM AA. 
 
Fig. 18 Viability of HMEC-1 treated with KB (βHB 2–20 mM and AA 0.5–5 mM). Data are expressed as mean ± 
SD. * p < 0.05 compared with control (βHB = 0 and AA = 0). 
3.2.2 Genotoxicity of ketone bodies 
Figure 19 shows the results relating to DNA damage, both in cells supplemented with KB (βHB 4 
mM and AA 1 mM) for 2, 24 and 48 h and control cells. KB induced moderate (<30%) (Klinder et al., 
2007) stress to cells at every incubation time point; in particular, it was found that DNA damage, 
expressed as the percentage of DNA in the tail, was about to 21% in KB-treated cells vs. 2% in 
control cells (C = 2.03 ± 0.21, KB2h = 19.25 ± 2.04, KB24h = 21.09 ± 4.20, KB48h = 23.75 ± 2.02% of DNA 
in the tail, p < 0.001). The results show that the DNA damage induction was not related to the 
duration of incubation, but it occurred rapidly.  
 
Fig. 19 Analysis of DNA damage in cells treated with KB (4 mM βHB, 1 mM AA) for 2, 24, 48 h; results are 
expressed as the % of DNA in the tail (mean ± SD). Data not sharing a common letter are significantly different, 
p < 0.001. 
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Then, we investigated the ability of KB to modulate DNA susceptibility toward a secondary 
oxidative insult. To this aim, cells were supplemented with KB (again for 2, 24 or 48 h) or not 
(control), and subsequently subjected to H2O2 50 μmol/L for 5 min. Firstly, there was a net increase 
in oxidative DNA damage in control cells exposed to H2O2 (C = 2.03 ± 0.21 vs. C + OX = 60.92 ± 2.73, 
% DNA in the tail, p < 0.001); cells previously treated with KB and exposed to H2O2 showed DNA 
damage as well. However, DNA damage decreased when the duration of exposure to KB increase. 
In particular, there was a significant decrease (−36%, p < 0.001), in H2O2-induced oxidative DNA 
damage in the cells treated with KB for 48 h (KB48 + OX = 39 ± 2.42% DNA in the tail) compared to 
the oxidized control cells (C + OX = 60.92 ± 2.73% DNA in the tail) (Fig. 20).  
 
Fig. 20 Analysis of DNA damage in HMEC-1 cells treated with KB (4 mM βHB, 1 mM AA) for 2, 24 or 48 h and 
subsequently oxidized with 50 μM H2O2 for 5 min; results are expressed as the % of DNA in the tail (mean ± 
SD). Data not sharing a common letter are significantly different, p < 0.001. 
3.2.3 Gene and protein expression of Nrf2 
Since we hypothesized a rapid activation of Nrf2 pathway, HMEC-1 cells were exposed to KB for 
shorter times (2, 6, 14 and 24 h). Firstly, regarding the gene expression of Nrf2, a significant increase 
was observed at 2 h in KB-treated cells compared to control cells (variation about 13%, p < 0.05). At 
later time points, instead, there was a decrease in Nrf2 mRNA levels (Tab. 7).  
Control KB 2h KB 6h KB 14h KB 24h 
0.89 ± 0.02a 1.01 ± 0.01b 0.82 ± 0.08a 0.66 ± 0.03c 0.58 ± 0.01c 
Tab. 7 Nrf2 mRNA expression by real-time PCR in control HMEC-1 cells and cells treated with KB for 2, 6, 14 
or 24 h. mRNA expression was normalized to the level of the housekeeping gene GAPDH. Data are the means 
± SD of three independent experiments. Data not sharing a common letter are significantly different, p < 0.05. 
The western blot analysis (Fig. 21) showed an increase in the total amount of Nrf2 at 2 h (by about 
30%) in cells treated with KB compared to the control cells. Furthermore, considering only the 
nuclear extracts, the amount of Nrf2 was greater in KB-treated cells than in the control. Particularly, 
as reported in Fig. 21C, the level of Nrf2 in the nucleus was significantly different at 2 h in cells 
treated with KB compared to control cells (KB2h = 50.30 ± 2.2; Control = 34.95 ± 2.9, % vs. total, p < 
0.05).  
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Fig. 21 Western blot analysis. Nrf2 protein expression in control cells or cells treated with KB for 2, 6, 14 or 24 h 
in the nuclear (A) and cytoplasmic (B) fractions. Lamin A/C was used as a nuclear marker. GAPDH was used 
as a cytoplasmic marker. The western blot image is representative of four independent experiments (A,B). 
Densitometric analysis of Nrf2 protein expression was performed using lamin A/C as the loading control and 
Nrf2 nuclear translocation are expressed as the % of Nrf2 in the nuclear fraction compared to the total amount 
of Nrf2 in whole cells. Data are the mean ± SD of four independent experiments. Data not sharing a common 
letter are significantly different, p < 0.05 (C). 
Moreover, the western-blot results were further confirm by immunofluorescence analysis. In fact, as 
we can see from figure 22, the nuclei of KB cells are brighter than the control after 2 h of treatment, 
indicating Nrf2 translocation in the nucleus and, therefore, its activation. 
 
Fig. 22 Immunofluorescence analysis with anti-Nrf2 antibody in control and KB-treated cells for 2 hours 
(original magnification 20x). 
3.2.4 HO-1 gene expression 
Activation of the Nrf2 pathway was investigated by assessing the gene expression of HO-1. The 
results show that HO-1 mRNA levels were significantly higher in cells treated with KB compared to 
control cells, at all time points measured (Tab. 8). Particularly, after 2 and 6 h there were the greatest 
increases in mRNA levels (C = 0.40 ± 0.05, KB2h = 1.00, KB6h = 0.91± 0.01, p < 0.05), while at later 
time points, although there was a decrease, the values were still higher than in control cells. 
Control KB 2h KB 6h KB 14h KB 24h 
0.40 ± 0.05a 1.00b 0.91 ± 0.01b 0.53 ± 0.09c 0.65 ± 0.03c 
Tab. 8 Real time PCR analysis of HO-1 mRNA expression in control HMEC-1 cells and cells treated with KB for 
2, 6, 14 or 24 h. mRNA expression was normalized to the level of the housekeeping gene GAPDH. Data are the 
means ± SD of three independent experiments. Data not sharing a common letter are significantly different, p < 
0.05. 
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3.3 DISCUSSION 
Although KD is used for multiple applications, less is known about its global impact on human 
body. In fact, the mechanisms by which KD achieves neuroprotection have been investigated by 
several studies (Noh et al., 2006 - Jarrett et al., 2008 - Milder & Patel, 2012), whereas the systemic 
effects of KB circulating in the bloodstream are not completely understood. Moreover, the adverse 
effects of KD on the cardiovascular system are still controversial. In fact, in epileptic patients 
following a KD treatment, has been observed an increase of serum levels of cholesterol, triglycerides 
and LDL, that are risk factors for cardiovascular diseases (CVD) (Kang et al., 2004 – Coppola et al., 
2014). In addition, changes in vascular function and structure have been reported (Kapetanakis et 
al., 2014). Instead, in non-epileptic subjects, the consumption of a KD has been associated with an 
improvement in some cardiovascular risk factors, even though the effect of long term use of KD and 
its lipid composition should be better assessed (Kosinski & Jornayvaz, 2017). Another important 
risk factor for CVD is endothelial dysfunction, often resulting from cellular oxidative unbalance 
(Drexler 1997 – Anderson et al., 1995). In this context, considering that KB exposure has been shown 
to alter red-ox cellular state, it appears critical to investigate the KB effects on endothelial model. For 
these reasons, we decided to investigate the effects of exposure to KB in HMEC-1 endothelial cells 
by measuring markers of oxidative stress and metabolic responses.  
Conflicting data are reported in literature concerning the production of ROS by KB and KD in 
different models. Some studies (Stafford et al., 2010 – Shukla et al., 2014) found ROS reduction owing 
to KB metabolism, while other studies reported increased oxidative stress (Allen et al., 2014), or no 
change (Poff et al., 2015) in cancer models. In primary cells, Veech reported that the metabolism of 
KB should reduce the amount of Q semiquinone, thereby decreasing ROS production (Veech, 2001). 
Conversely, other investigations in primary cells models showed different results. For instance, Shi 
et al. investigated the pro-oxidant activities of βHB in primary calf liver cells; they demonstrated 
that βHB decreased antioxidant defences and increased the oxidizing species, causing stress at least 
within 24 h (Shi et al., 2014). Another study seems to confirm this thesis, because it showed that, in 
mitochondria from the hippocampus of rats fed a KD, there was an increase both of H2O2 and 
4-HNE levels, markers of oxidative stress. These results suggest the induction of mild oxidative 
stress immediately after the beginning of a KD (Milder et al., 2010). More specifically of our interest, 
it has been demonstrated that ketones can generate oxygen radical and overall contribute to 
increased oxidative stress also in endothelial cells. For instance, the study of Kanikarla-Marie et al., 
showed that KB cause increased oxidative stress by up-regulating NADPH oxidase 4 in HUVEC 
cells (Kanikarla-Marie & Jain, 2015). Accordingly, another research demonstrated that elevated 
levels of KB can result in lipid peroxidation, which is supposed to be increased by oxygen radicals 
generated by AA (Jain et al., 1998). Thus, our results are in agreement with these recent data, as they 
demonstrate that KB, at concentrations equal to 4 mM for HB and 1 mM for AA, induced moderate 
oxidative stress. Although they significantly increased oxidative DNA damage after 2 h, we 
detected that this stress was not related to the duration of exposure. In fact, we did not find any 
significant differences in DNA damage among the three time points of exposure (2, 24 and 48 h). 
Therefore, we hypothesized that, during 48 h of treatment, the oxidative stress generated at 2 h may 
induce some cellular metabolic responses. One of the protective mechanisms promoted by the cell 
as a consequence of KB-induced stress could be the activation of antioxidant enzymes. 
With the aim to investigate this hypothesis, we exposed HMEC-1 cells to KB and afterwards to a 
secondary oxidative insult, in our study represented by H2O2. Surprisingly, oxidized cells 
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previously treated with KB for 48 h showed significantly less DNA damage compared to control 
oxidized cells. This intriguing result suggests that KB cause moderate oxidative stress and, at a 
following time point, they can activate a cellular response that results in protection against a 
secondary insult. 
Lately, several studies have been carried out to understand the positive role of KB in some 
pathologies, not only epilepsy, but also other neurological diseases and cancer. For instance, a study 
published by Noh et al. proved that AA protects neuronal cells from oxidative glutamate toxicity. In 
particular, cells treated with AA showed a significant decrease in glutamate-induced ROS 
production compared with cells treated with glutamate alone (Noh et al., 2006). Moreover, Shimatzu 
and collegues implanted mice with subcutaneous pump delivering PBS or βHB for 24 h, in order to 
test the potential protective role of βHB against oxidative stress. Then mice received an intravenous 
injection of paraquat, which produces superoxide anions. The authors found that paraquat 
treatment of HB-treated mice led to a significant prevention of carbonylated proteins, while in 
control mice there was an increase of their production. Equally, the increase of 4-HNE was 
suppressed in mice receiving βHB, compared to PBS-treated mice (Shimazu et al., 2013). Likewise, 
Jarrett et al., reported that KD increased mitochondria reduced glutathione (GSH) levels and 
improved red-ox status, thereby resulting in decreased mitochondrial production of ROS in rats fed 
a KD for three weeks (Jarrett et al., 2008). Consistently with the papers above, our data suggest the 
capacity of KB to promote cellular responses that result in the prevention of oxidative damage 
induced by a secondary insult, maybe by implementing the antioxidant defences. 
The activation of the Nrf2 pathway may be a potential mechanism by which this protection occurs 
(Milder & Patel, 2012 – Liśkiewicz et al., 2016). Nrf2 is a transcription factor normally sequestered in 
the cytoplasm by binding to the protein Keap1 (kelch ECH associating protein 1), which continually 
ubiquitinates Nrf2, targeting it for the proteasome where is degraded. When stress occurs, Keap1 is 
inactivated and Nrf2 is stabilized, therefore, de novo synthesized Nrf2 translocates into the nucleus. 
There, it forms a heterodimer with small Maf (sMaf) proteins and activates the transcription of 
target genes by binding to antioxidant response elements (ARE) (Lee & Johnson, 2004 - Kobayashi & 
Yamamoto, 2005 - Kensler et al., 2007 - Bryan et al., 2013 - Kim & Keum, 2016). Some studies have 
reported that enhanced nuclear translocation of Nrf2 protects against oxidative stress injury (Gu et 
al., 2015 – Liao et al., 2016). For these reasons, firstly we decided to evaluate Nrf2 gene expression, 
then its translocation into the nucleus. Since we hypothesized that the activation of a cellular 
response would happen fast, as we saw protection at 48 h, we exposed HMEC-1 cells for 2, 6, 14 or 
24 h to KB. Primarily, the gene expression results showed higher mRNA Nrf2 levels at 2 h; thus, it 
seems that there was very rapid stabilization of Nrf2, which implies its fast de novo synthesis. 
However, the levels of Nrf2 mRNA expression from 6 to 24 h were lower, but we cannot say that 
Nrf2 was non-active. Indeed, it has been indicated by several papers that some agents can increase 
the nuclear translocation of Nrf2, but not alter its gene expression level (Ishii et al., 2000 - Nguyen et 
al., 2003 - Liao et al., 2016). Accordingly, the findings obtained from the western blot analysis 
showed an increase in the total amount of Nrf2 in KB-treated cells compared to control as well as 
nuclear accumulation already at 2 h. This result was further confirmed with the immunoflorescence 
analysis. The trend of increased Nrf2 nuclear accumulation means that the association between 
Keap1 and Nrf2 has changed; the transcription factor was stabilized and was not degraded by the 
proteasome anymore, therefore its translocation into the nucleus was promoted. In view of these 
data, we hypothesized that KB, at first, cause the production of low levels of ROS, which may serve 
as a redox signaling stimulus and activate the transcription factor Nrf2. Milder and colleagues were 
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the first to propose that the consumption of KD could activate the Nrf2 pathway. In fact, they 
observed Nrf2 accumulation in nuclear fractions from the hippocampus and liver of rats fed a KD 
for up to three weeks, suggesting chronic Nrf2 nuclear translocation and activation (Milder & Patel, 
2012). Newly, the impact of KD on tumor growth in an animal model was investigated; the authors 
reported that, among the several factors protecting against cancer, one was the stimulation of Nrf2 
(Liśkiewicz et al., 2016). Both of these studies clearly showed higher Nrf2 nuclear levels, even the 
different dietary intervention with KD. 
In order to confirm the effective involvement of the Nrf2 pathway, we decided to analyze the gene 
expression of one of its target genes: HO-1. It is one of the most important enzymes up-regulated by 
Nrf2, its function is to catalyze the conversion of heme into biliverdin, carbon monoxide and free 
iron, and it has both anti-inflammatory and antioxidant properties (Immenschuh & Ramadori, 2000 
- Paine et al., 2010 - Loboda et al., 2016). Moreover, among the antioxidant proteins regulated by 
Nrf2, we chose HO-1 because its induction is strongly related to the red-ox-dependent Keap1/Nrf2 
system when stress occurs (Paine et al., 2010 – Liao et al., 2016). Our results confirm the activation of 
Nrf2/HO-1 pathway, because they showed, at all time points, an increase in HO-1 gene expression, 
particularly after 2 and 6 h of KB exposure, accordingly with other papers (Yao et al., 2007 - Chen et 
al., 2011 - Liao et al., 2016). It has been shown by several studies that activation of the Nrf2/HO-1 
pathway protects different types of cells (Nguyen et al., 2003 - Gu et al., 2015 - Liao et al., 2016) and, 
particularly, this pathway has been specifically correlated to the effects of KD. In the study 
mentioned above by Milder et al., a new mechanism of action of KD has been suggested, which 
include Nrf2 activation. The authors proposed that the Nrf2 pathway was systemically activated by 
KD via redox signalling, resulting in the induction of protective proteins and cellular adaptation. In 
fact, their results showed that, after the consumption of a KD, both Nrf2 and HO-1 protein 
expression were higher compared to control (Milder & Patel, 2012). This hypothesis has been 
confirmed further, by Liśkiewicz and collegues, with the investigation of the long-term effects of 
KD on tumor growth. Indeed, they demonstrated that Nrf2 levels increased in rats fed a KD 
compared to control (Liśkiewicz et al., 2016). Hence, our results, accordingly to the studies reported, 
overall demonstrate rapid activation of Nrf2 pathway after KB-induced stress. 
More detailed analysis should be performed in upcoming studies, planned to evaluate the effects of 
AA and βHB individually supplemented, with the aim to clarify their specific influence on DNA 
oxidative damage and Nrf2 activation. Additionally, the expression of other Nrf2 target genes, 
different from HO-1, should be assessed, to confirm KB activation of Nrf2 pathway once again. 
3.4 CONCLUSIONS 
The results obtained in this in vitro study demonstrate the activation of a cellular metabolic response 
caused by the effect of KB exposure. The conclusions of this project are graphically summarised in 
Fig. 23. Ketones, by inducing moderate oxidative stress, activate the transcription factor Nrf2, which 
translocates into the nucleus. By binding to the ARE, Nrf2 activates the transcription of target genes, 
among which HO-1. As a consequence, the metabolic response caused by KB exposure makes cells 
more protected against a secondary insult, such as H2O2, leading to a reduction in DNA oxidative 
damage.  
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Fig. 22 Proposed mechanism of action of KB in HMEC-1 cells. 
The choice to investigate the effects of KB in endothelial cells is a novelty in this field of research, 
since it is something different from the neurological context. Although the positive effects of the 
ketogenic therapy have been clearly demonstrated (Freeman et al., 1998 – Tieu et al., 2003 - Hartman 
& Vining, 2007 – Kashiwaya et al., 2013), the use of this diet as a weight loss method is still 
controversial. Every time a KD is applied it should be considered that this diet could have an impact 
on cell metabolism in different tissue functions. The mechanism hypothesized in our in vitro study is 
that KB could activate the transcription factor Nrf2, which improves the cellular ability to detoxify 
and remove harmful substances by the activation of cellular defence processes (Lee & Johnson, 2004 
– Uruno & Motohashi, 2011 – Bryan et al., 2013). However, the up-regulation of Nrf2 does not 
always leads to protection; for instance, it has been reported that it may promote carcinogenesis in 
various tissues. This is due to different activities of Nrf2: improvement of mitochondrial function, 
suppression of apoptosis, and redirection of glucose metabolism toward NADPH generation and 
anabolic pathways, which overall generate cell proliferation (Holmström et al., 2013 - Suzuki & 
Yamamoto, 2015 - Tebay et al., 2015). Moreover, considering the activation of Nrf2 as a result of 
impaired oxidative cell status, it could be harmful promote this function in the long term. In 
conclusion, when a KD is applied, both for therapeutic or weigh loss purposes, a careful 
examination of the risk-benefit ratio should be done. 
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4.1 SUBJECTS AND METHODS 
4.1.1 Study design 
In order to study the effects of the KD on human intestinal environment, and verify if there are any 
differences in microbiota composition respect to a standard diet, a case-control observational 
multi-center study was designed. We enrolled 12 patients (6 females and 6 males, age range 2-46 
years) affected by GLUT1-DS or refractory epilepsy, both pathologies for which KD is mandatory, 
at the Department of Child Neurology and Psychiatry of C. Mondino National Neurological 
Institute in Pavia. They were matched to a respective control group represented by a healthy 
population, comparable by gender, age and body mass index; these subjects were recruited at the 
Pediatric Clinic of the San Paolo Hospital in Milan.  
Exclusion criteria were: fecal incontinence; gastrointestinal disorders or use of antibiotic or 
probiotic/prebiotic supplements during the month prior to the study; treatment with antiepileptic 
drugs at the time of the study, age < 2 years old.  
The recruitment (Fig. 23) began in September 2016 and lasted untill June 2018. In this period, 33 
patients were diagnosed of refractory epilepsy or GLUT1-DS and undergoing a ketogenic diet, 
implemented as a therapy at the Human Nutrition Research Center in Pavia. We faced numerous 
recruitment challenges, mostly because the majority of subjects (21) did not have fecal continence, 
therefore they were unsuitable for the study.  
 
Fig. 23 Patients selection and enrollment 
Partecipants enrolled to the study, both under KD treatment (KD) and controls (CTR), received 
specific instructions for the total collection of a fecal sample. 
In addition, a 1-month, prospective, single-center, single-arm study of the effects of the KD on gut 
microbiota was designed (Fig. 24), with the aim to investigate the specifc effect of KD beside the 
pathological condition. To this aim, we enrolled 7 patients (4 females and 3 males, age range 2-46 
years) affected by GLUT1-DS or refractory epilepsy, at the Department of Child Neurology and 
Psychiatry of C. Mondino National Neurological Institute in Pavia; they were asked to collect a fecal 
sample before (t0) and after one month of treatment with a classic KD (t1). 
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Fig. 24 Schematic diagram indicating experimental protocol 
The study protocol complied with the principles of the Declaration of Helsinki, and was approved 
by the Institution Review Board. All patients (or parents if the patient was <18 years of age) 
provided written informed consent before the beginning of the study. The study purpose and 
protocol were exhaustively explained to all participants and their parents, who signed an informed 
consent before study enrollment.  
4.1.2 Ketogenic diet treatment 
The treatment with KD was implemented at the Human Nutrition Research Center outpatient clinic 
according to a standardized protocol (Tagliabue et al., 2012). The patient's protocol has provided for 
a first visit during which the information relating to the physiological and pathological history were 
gathered, anthropometric measurements (weight, height, BMI, bicipital, tricipital and subscapular 
folds, waist circumference) were recorded, biochemical tests (lipid profile, glycaemia, uric acid, 
creatinine) were performed, body composition assessment parameters (bioimpedentiometry, 
percentage fat mass) were predicted, and measured by indirect calorimetry, basal metabolic rate 
were measured. Prior to start the diet, blood tests were performed to check for contraindications, 
dyslipidemia, hyperuricemia or elevated levels of creatinine. Subsequently, surveys were carried 
out on the eating habits of patients through a very detailed 7-day food diary, both in terms of 
quantity and quality of food and drinks consumed during the day. 
After this evaluation the dietician worked out, for each patient, several individual and personalized 
KD plans. Firstly, the caloric needs were established considering an average between the measured 
basal metabolic rate, the energy intake obtained from the food diary and the level of physical 
activity of the patients (usually low). Proteins were established on the basis of population 
recommended intake levels based on sex and age of patients, while glucose/protein and lipid intake 
were calculated in relation to the ketogenic ratio of the diet followed by the patient (2:1 or 3:1 or 4:1). 
All patients were instructed to start a 1:1 ketogenic diet at home and gradually proceed to 2:1, 3:1 or 
4:1 ketogenic ratios in order to obtain blood values 2.0 mml/l of HB. Parallel to the reduction of the 
carbohydrate quantity and therefore to the limitation of the fruit and vegetable intake, it was 
evaluated the intake of a vitamin-mineral supplement to avoid any deficiencies. The integrator, 
strictly sugar free, must take into account age, sex of the patient, and established ketogenic 
relationship. Among the supplementations it was also recommend an adequate intake of liquids, 
favoring in consumption of water, preferably strongly mineralized, or alternatively drinks without 
sugar. No probiotic or prebiotic supplementation was provided in the first month of treatment. 
Families were instructed to check blood (for glucose and KB control) daily during the induction 
phase and twice per week thereafter, and to report the values by e-mail. 
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4.1.3 Collection and preparation of samples 
Patients were instructed to collect the total stool of one day in disposable bedpans, keep the sample 
refrigerated and deliver it to the laboratory within 24-48 h from the recovery. Aliquots of stool were 
immediately divided for different biological assessment and for preparation of fecal water, then 
were stored at -80°C. The humidity of fecal samples was determined, after drying at 105°C 
overnight, by weight difference of a sample aliquot according to the official AOAC method n. 923.03 
(AOAC 1995). 
4.1.3.1 Preparation of fecal water 
Fecal water (FW) was obtained, from frozen samples, after defrosting them for 2 hours at room 
temperature; then samples were diluted 1:1 (w/v) in sterilized PBS and homogenised manually until 
a uniform consistency was achieved. The samples, transferred into ultracentrifuge tubes (Beckman 
Ultra-clear tubes; Beckman Limited, High Wycombe, UK) centrifuged at 24000 rpm (35000g) for 2 h 
at 20°C (Beckman L7-55 Ultracentrifuge; Beckman Limited, High Wycombe, UK), and supernatants 
were carefully decanted and stored at -80°C. For citotoxicity and genotoxicity evaluation, FW 
samples were rapidly defrosted, centrifuged at 11.000 rpm for 2 min at 20°C to remove any residual, 
and filtered through 0,45m filter (VWR International, USA); filtered solutions were used to assess 
FW toxicity. 
4.1.4 Fecal water toxicity 
4.1.4.1 Cell culture 
Human Caco-2 cells were obtained from the European Collection of Animal Cell Cultures (United 
Kingdom). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma–Aldrich) supplemented with 10% heat inactivated (30 min at 56°C) fetal bovin serum, 2 mM 
L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mMnon-essential amino acids, in an 
incubator with an atmosphere of 95% air and 5% carbon dioxide. The culture medium was routinely 
changed every 2 days, and always the day before exposure to fecal water. All cell culture reagents 
were purchased from Sigma–Aldrich (St. Louis, MO, United States) and chemicals from Merck 
(Darmstadt, Germany). 
When cells reached a subculturing density of 70% confluence, they were detached by means of 
trypsinization: the medium was removed from the flask (75 cm2), and the cells were washed with 
PBS and treated with 2.5 mL of fresh trypsin–EDTA solution in the incubator. The trypsin action, 
lasting 5 min, was arrested by the addition of 4 mL of complete medium. The cell suspension was 
then transferred to a 15 mL tube and centrifuged 5 min at 1000g. After removing the supernatant, 
the cell pellet was resuspended in complete medium and seeded at 104 cells/cm2 (Natoli et al., 2012). 
4.1.4.1.1 Cell differentiation  
When Caco2 cells differentiated, an in vitro system is obtained that simulates both the morphology 
and the functionality of the human intestinal epithelium. In fact, the differentiated Caco2 cells 
express narrow junctions, microvilli and a series of enzymes typical of enterocytes (Fig. 25) (Sambuy 
et al., 2005). 
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Fig. 25 Image of Caco-2 cells obtained by optical microscope (A) and electron microscope (B). The cell is 
polarized, that is with the microvilli, intended for the absorption of nutrients, exposed upwards, in the 
direction of the culture medium, which corresponds to the intestinal lumen. The adjacent cells are joined by 
tight junctions. 
For toxicity experiments, considering the permeability of the tight junctions determined by 
measurements of trans epithelial electric resistance of cell monolayers, cells were seeded on 60mm 
plates (Cellstar, Greiner, Germany) at a density of 105 cells/cm2, maintained for 10 days in complete 
medium; the medium was changed three times a week (Sambuy et al., 2005).  
4.1.4.2 Citotoxicity and genotoxicity 
A suspension of differentiated Caco-2 cells (3.5 x 105 cells/ml in 380 L) was incubated with FW (120 
L) or medium (120 L negative control) or H2O2 500 M (120 L positive control) for 30 min at 37°C 
on a shaking platform (Erba et al., 2014). Every FW recovered from stool samples was analyzed in 
quadruple and controls (negative and positive) were included in each batch. After the incubation, 
an aliquot of this cell suspension was used to assess citotoxicity of FW, by measuring cell viability, 
with Trypan Blue exclusion test (expressed as percentage of viable cells). Another aliquot of cell was 
used to assess genotoxicity of FW with Comet Assay, according to the procedure previously 
described (3.1.4). 
4.1.5 SCFA measurement 
SCFA concentrations were assessed in accordance with the method proposed by Weaver et al. 
(1997), modified as follows. Stool (200 mg) were suspended in 1 mL of double distilled water, 
homogenized on a vortex mixer, and, after 30 min, centrifuged (15000 rpm) for 15 min at 10°C 
(Beckman Coulter Centrifuge). Aliquots (0.5 L) of supernatant were added with 200 L 85% 
orthophosphoric acid, and 300 L of 2-ethyl-butyric acid (109959 Sigma-Aldrich,Milan, Italy) 3.3 
mM in H2SO4 2% as internal standard. SCFA were gently extracted for 1 min with 1 mL 
ethyl-ether/heptan (1:1 v/v) and centrifuged for 10 min at 3000 rpm. The aqueous phase was frozen 
and the organic layer was removed for analysis by a Varian 3400 CX (Conquer Scientific, San Diego, 
CA, USA) gas liquid chromatograph equipped with a Varian 8200 CX autosampler and an 
HP-FFAP fused-silica capillary column (30 m, 0.53 mm i.d. with a 1-mm film). Injector and detector 
temperatures were 90°C and 260°C, respectively. The initial oven temperature was 60°C and was 
increased by 5°C/min to 130°C and then by 20°C/min and held at 200°C. Quantification of the SCFA 
was obtained through calibration curves of acetic, propionic, iso-butyric, butyric, and iso-valeric 
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acid in concentrations between 0.5 and 10 mM (10 mM 2-ethyl-butyric acid as internal standard) 
(Weaver et al., 1997). Results are expressed as mg/g of dry weight of feces. 
4.1.6 Gut microbiota analysis 
Stool total bacterial DNA extraction was performed using the Spin stool DNA kit (Stratec 
Molecular, Berlin, Germany), according to the manufacturer's instructions. Twenty-five ng of DNA 
extracted from each stool sample was utilized to construct a sequencing library. 16S rRNA gene 
amplicon libraries were performed with a two-step barcoding approach according to Illumina 16S 
Metagenomic Sequencing Library Preparation (www.illumina.com). In the first-step PCR, 16S 
rRNA genes (V3-V4 region) of all bacteria were amplified as described by Klindworth et al. (2013). 
For library preparation, DNA samples coming from first PCR step were amplified with dual-index 
primers using Nextera DNA Library Preparation Kit (Illumina, San Diego, CA, USA).  
Each sample possessed specific barcode sequences at the 5’- and 3’-end of the PCR amplicon to 
discriminate among each other in the pooled library. Library concentration and exact product size 
were measured using a KAPA Library Quantification Kit (Kapa Biosystems, Woburn, MA, USA) 
and an Agilent 2100 Bioanalyzer System (Agilent, Santa Clara, CA, USA), respectively. 
A pooled library (20 nM) and a PhiX control v3 (20 nM) (Illumina) were mixed with 0.2 N fresh 
NaOH and hybridization buffer HT1 (Illumina) to produce the final concentration at 12 pM each. 
The resulting library was mixed with the PhiX control v3 (5%, v/v) (Illumina) and 600 µL loaded on 
a MiSeq® v2 (500 cycle) Reagent cartridge for obtaining a paired-end 2 × 250 bp sequencing. All 
sequencing procedures were monitored through the Illumina BaseSpace® application. FASTQ files 
were demultiplexed by Illumina MiSeq Reporter and a total of 2.5 Gbases raw reads were obtained. 
Sequencing reads are available in NCBI Short Read Archive (SRA, 
http://www.ncbi.nlm.nih.gov/sra) under accession number PRJNA447916.  
 
4.1.6.1 Microbiota profiling 
The 16S rRNA sequences obtained were analyzed using Pandaseq (Masella et al., 2012). Low quality 
reads were filtered and discarded, then the reads were processed using the QIIME pipeline (release 
1.8.0; Caporaso JG et al., 2011) and clustered into Operational Taxonomic Unit (OTUs) at 97% 
identity level. Taxonomic assignment was performed via RDP classifier (Wang et al., 2007) against 
the Greengenes database (release 13_8  http://greengenes.secondgenome.com).  
Alpha-diversity was computed through the QIIME pipeline using Chao1, observed species, 
Shannon diversity and Faith’s Phylogenetic diversity metrics; statistical evaluation of differences in 
alpha-diversity indices was performed by a non-parametric Monte Carlo-based test, using 9999 
random permutations. Beta-diversity’s principal coordinates analysis (PCoA) was performed using 
weighted and unweighted UniFrac distances, while “adonis” and “anosim” functions were 
employed to determine statistical separation of the microbiota profiles. 
 
4.1.6.2 Real-time PCR quantification 
Absolute quantification by real-time PCR was performed before and after KD in 7 patients. After 
extraction with the Prepman Ultra kit (Applied Biosystem, USA), the DNA of the following control 
strains was used to determine the standard curves: Roseburia intestinalis DSM 14610 and 
Faecalibacterium prausntzii DSM 17677 from the international DSMZ (Leibniz-Institut 
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DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH). The other 
microorganisms used as a control are part of the collection of the Laboratory of Clinical 
Microbiology of the Department of Health Sciences of the University of Milan: Bifidobacterium 
animalis and Enterobacteriaceae. 
Real Time PCR was carried out using the StepOne Plus instrument (Applied Biosystems) and the 
SYBR1Green chemistry (ThermoScientific, USA). The analysis was performed in a total volume of 
15 μl, and each sample analyzed in triplicate. Standard curve was carried out using five serial 
dilutions of control DNA and specific 16S rRNA primers reported in Tab 9. 
 
 PRIMER 
5’ -> 3’ 
Enterobacteriaceae fw: CAT TGA CGT TAC CCG CAG AAG AAG 
rev: CTC TAC GAG ACT CAA GTC TGC 
Bifidobacterium spp. fw: CGC GTC YGG TGT GAA AG 
rev: CCC CAC ATC CAG CAT CCA 
Roseburia spp. fw: TAC TGC ATT GGA AAC TGT CG 
rev: CGG CAC CGA AGA GCA AT 
Faecalibacterium prausnitzii fw: GGA GGA AGA AGG TCT TCG 
rev: AAT TCC GCC TAC CTC TGC ACT 
Tab. 9 Forward and reverse primers of the species in analysis. 
The following thermal cycling parameters were used for amplification of DNA: 95°C for 10 minutes 
followed by 40 cycles of 20 seconds at 95°C, 3 seconds at 95°C, and 30 seconds at 60°C. A melting 
curve analysis was also performed to verify amplicon specificity. 
4.1.7 Statistical analysis 
Variables are expressed as means and standard deviations. Because of the paired data, comparisons 
of continuous variables before and after 1 month of KD were performed by the paired t-test. All 
calculations were performed using SPSS version 17.0 for Windows (SPSS, Inc., Chicago, IL, USA). A 
value of p-values < 0.05 (two sided) was considered statistically significant. 
For microbial profiling, statistical comparisons were performed using MATLAB software (Natick, 
MA, USA). For evaluating differences in relative abundances of bacterial groups at each taxonomic 
level, a Mann-Whitney U-test was performed, excluding a normal distribution of data at every level 
(Shapiro-Wilk test at 0.99 confidence). Unless otherwise stated, p-values < 0.05 were considered as 
significant. 
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4.2 RESULTS 
4.2.1 KD vs CTR 
4.2.1.1 Gut microbiota analysis 
The gut microbiota was characterized by next-generation sequencing using V3–V4 hyper-variable 
16S rRNA genomic region. On average, 43492.000 high-quality reads were considered for gut 
microbiota analysis of KD (n = 11; one subject was excluded because he was too young compared to 
the others and showed completely different results) and healthy controls (n = 10); reads were then 
grouped in a total of 47917 operational taxonomic units (OTUs), which could be assigned to specific 
taxonomies down to the genus level.  
Firstly, bacterial composition within each sample (-diversity) was measured using OTU-based 
methods (Chao1, Fig. 27A; observed species, Fig. 27B; and Shannon indexes, Fig. 27C). 
 
Fig. 26  rarefaction curves according to Faith’s phylogenetic diversity index. -diversity plot of KD (blue) 
versus control (red) samples. KD patients show a reduced biodiversity compared to healthy controls. 
Differences are statistically significant (p < 0.05) for Chao1 (A), not for observed species (B) or Shannon indexes 
(C). 
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Even though we could observe a reduction in -diversity in KD group, the number of subjects 
analyzed was not sufficient to reach statistical significance (p < 0.05, permutation-based 
non-parametric t-test) for all metrics, but only for Chao1 index. 
Furthermore, to investigate differences in the two studied groups, we assesed -diversity using 
weighted (Fig. 27A) and unweighted (27B) UniFrac distances. 
 
Fig. 27 Principal Coordinate Analysis (PCoA) according to unweighted (A) and weighted (B) Unifrac distances. 
The first two components of the variance are represented. PCoA of KD (blue) versus CTR (red) samples. 
Differences are statistically significant (p < 0.05).  
-diversity analysis highlighted a statistically significant separation between the centroids of KD 
and CTR groups according to the weighted and unweighted Unifrac distance (p = 0.001; p = 0.002, 
respectively). This important difference may be due to principal components of the gut microbiota, 
as the separation for both Unifrac metric was significant.   
To evaluate possible differences in taxa distribution among KD and control subjects we analyzed 
the relative microbial abundance at different taxonomic levels. At the phylum level (28A) 
Bacteriodetes and Firmicutes were the predominant bacteria taxa in feces of both KD and CTR; in 
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particular, these two taxa rapresent 96.4% (CTR) and 92.8% (KD) of total microbiota. However, data 
showed a different ratio Firmicutes/Bacteriodetes, as Firmicutes were significantly increased in KD 
compared to CTR (KD: 81.9 ± 10.8, CTR: 59.3 ± 12.4; mean ± sd, p < 0.001), on the contrary 
Bacteroidetes were reduced (KD: 10.9 ± 10.1, CTR: 37.1 ± 10.7, p < 0.001).  
Accordingly, this difference was reflected also in the results of the family level (Fig. 28B), as we 
detected a significant decrease in Bacteroidaceae (KD: 7.8 ± 6.9, CTR 30.3 ± 10.7, p < 0.001) and an 
increase, in Ruminococcaceae, although not statistically significant (KD: 39.0 ± 14.6, CTR: 31.3 ± 13.1, p 
= 0.42). Moreover, KD showed significant differences in other smaller families, particularly in 
Lachnospiraceae, Rikenellaceae and Erysipelotrichaceae (KD: 24.1 ± 10.9, 0.7 ± 0.8, 1.1 ± 0.8; CTR: 13.7 ± 
4.4, 3.1 ± 2.2, 0.4 ± 0.3; respectively, p < 0.05).  
 
Fig. 28 Bar charts representing the average relative abundance of subjects on a ketogenic diet (KD) and healthy 
control (CTR) microbiota, classified using the 16S rRNA gene. A) Mean relative abundances of fecal bacterial 
phyla; B) Mean relative abundances of fecal bacterial families. 
At the genus level (Tab. 10), the most important results, statistically significant, were the reduction 
in Bacteroides (KD: 7.8 ± 6.9, CTR: 30.3 ± 10.7, p < 0.001) and the increase in unclassified 
Ruminococcaceae (KD: 15.5 ± 13.2, CTR: 6.7 ± 7.2, p < 0.05). Moreover, in KD group we found a 
significant decrease of the genera Unclassified Rikillenaceae (KD: 0.63 ± 0.75, CTR: 2.83 ± 2.11, p < 0.05) 
and Veillonella (KD: 0.36 ± 0.33, CTR: 1.60 ± 2.34, p < 0.05); on the contrary, a statistical significant 
increase was observed for Blautia (KD: 2.83 ± 3.17, CTR: 0.90 ± 0.72, p < 0.05), Unclassified 
Erysipelotrichaceae (KD: 1.11 ± 0.68, CTR: 0.45 ± 0.33, p < 0.05), Prevotella (KD: 0.85 ± 0.78, CTR: 0.08 ± 
0.006, p < 0.05). 
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Genus Relative abundance  
 KD CTR  
 Mean SD Mean SD p-value 
Bacteroides 7.78 6.97 30.29 10.74 0.00 
Unclassified Ruminococcaceae 15.46 13.16 6.71 7.27 0.05 
Faecalibacterium 9.00 10.46 10.78 6.30 0.34 
Dialister 4.55 7.17 4.04 5.48 0.68 
Unclassified Clostridiales 7.24 9.32 6.00 6.58 0.97 
Unclassified Lachnospiraceae 5.68 3.01 3.76 2.58 0.24 
Roseburia 6.97 6.36 2.99 1.59 0.16 
Escherichia 3.00 6.11 0.86 2.09 0.88 
Ruminococcaceae (other) 2.98 2.89 3.65 3.12 0.97 
Oscillospira 6.91 8.82 3.79 2.36 0.91 
Ruminococcus 3.92 2.54 5.77 5.19 0.43 
Akkermansia 3.14 5.05 0.64 1.07 0.09 
Blautia 2.89 3.17 0.90 0.72 0.05 
Coprococcus 2.83 2.19 1.74 1.75 0.16 
Unclassified Rikenellaceae 0.63 0.75 2.83 2.11 0.00 
Lachnospira 0.50 0.54 1.08 1,33 0.68 
Clostridium 1.98 4.20 0.54 0.84 0.32 
Unclassified Erysipelotrichaceae 1.11 0.68 0.45 0.33 0.01 
Veillonella 0.36 0.33 1.60 2.34 0.03 
Prevotella 0.85 0.78 0.08 0.06 0.00 
Desulfovibrio 0.01 0.02 0.19 0.32 0.35 
Tab. 10 Relative abundances of fecal bacterial genera of subjects on a ketogenic diet (KD) and healthy control 
(CTR); data are expressed as means ± standard deviations. 
4.2.1.2 SCFA levels   
Changes in microbial species may alter the amounts of microbial metabolites, in particular SCFA, 
produced as fermentation products from food components that are undigested in the upper 
intestine. Concentrations of SCFA, expressed as mg/g dry weight feces, in the two groups of 
analysis, are reported in Tab. 11. We found a significant statistical difference between CTR and KD 
for all the SCFA measured (p < 0.05), except for butyrate ( p = 0.065). SCFA were strongly reduced in 
patients on a KD compared to healthy subjects. This result is consistent with the gut microbiota 
analysis, which showed a depletion of Bacteroidetes, able to ferment indigestible polysaccharides 
and produce SCFA.  
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Fecal SCFA (mg/g dry feces) 
 KD CTR  
 Mean SD Mean  SD p-value 
total SCFA 10.56 5.9 23.1 8.5 0.005 
Acetate 4.31 2.9 11.13 4.4 0.003 
Butyrate 3.18 1.9 5.1 1.7 0.065 
Propionate 2.14 1.2 4.52 2 0.008 
Iso-valerate 0.59 0.3 1.43 0.6 0.002 
Iso-butyrate 0.35 0.2 0.96 0.5 0.002 
Tab. 11 Fecal SCFA concentrations in patients on a ketogenic diet (KD) and healthy controls (CTR). Data are 
expressed as means ± standard deviation. 
4.2.2 Specific effect of KD on human gut 
4.2.2.1 Ketogenic dietary treatment 
Since we observed differences in microbiota composition and SCFA concentrations in patients 
undergoing a KD respect to healthy subjects followed a conventional diet, we wanted to further 
investigate the specific effect of this diet on human gut health. We selected 7 patients, who collected 
fecal samples before starting the dietary therapy and after 1 month of KD. Adherence to the KD 
protocol was documented by constant ketonuria in all subjects. All participants completed the 
protocol, tolerated the diet well, and there were no adverse effects. 
Table 12 shows the daily dietary intake before and after the beginning of the KD. The total energy 
intake did not differ significantly before and after the treatment with KD. In terms of nutritional 
composition, on the classical KD all macronutrients changed significantly; in particular fat 
(expressed as percentage of total dietary energy) increased from 44.7 ± 17.9% to 85.3 ± 4.0% kcal (p < 
0.05), while protein and carbohydrates (expressed as percentage of total dietary energy) were 
reduced from 14.5 ± 4.6% to 9.0 ± 2.9% (p < 0.05) kcal and from 38.1 ± 15.2% to 5.1 ± 3.4% (p < 0.05), 
respectively. 
  Pre intervention (t0) Post Intervention (t1)   
  Mean SD Mean  SD p-value 
Energy Intake (kcal/24h) 1432.3 424.6 1512.1 320.7 0.499 
Energy Intake (kcal/kg) 57.1 33.3 57.3 28.6 0.932 
Protein (g/kg) 1.8 0.8 1.2 0.3 0.030 
Protein (% energy) 14.5 4.6 9.0 2.9 0.005 
Carbohydrates (g/kg) 2.1 1.2 0.9 1.1 0.150 
Carbohydrates (% energy) 38.1 15.2 5.1 3.4 0.001 
Fat (g/kg) 2.8 2.0 5.4 2.7 0.015 
Fat (% energy) 44.7 17.9 85.3 4.0 0.001 
Saturated Fat (% energy) 14.3 8.0 22.3 8.6 0.142 
Monounsaturated Fat (% energy)  12.5 6.2 29.2 6.6 0.000 
Polyunsaturated Fat (% energy) 4.3 2.9 12.0 4.6 0.000 
Cholesterol (mg/day) 171.7 101.1 200.8 107.8 0.623 
Tab. 12 Daily dietary intake before and after the treatment with KD. 
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4.2.2.2. Humidity of fecal samples 
We decided to evaluate the humidity of fecal samples in order to assess differences intra-subject; 
results are reported in Tab. 13. Although this parameter was quite different among the 7 patients, 
only for one subject (4) we found differences before and after the diet. Moreover, the values 
obtained were used to report SCFA concentrations as mg/g dry weight feces. 
 Humidity (%) 
subjects t0 t1 
1 77.9 78.8 
2 65.9 61.4 
3 74.3 76.9 
4 81.9 64.8 
5 83.1 77.4 
6 55.5 55.0 
7 61.5 61.4 
Tab. 13 Humidity of fecal samples of 7 subjects before (t0) and after (t1) the diet. 
4.2.2.3 Changes in gut microbiota after KD 
To evaluate possible differences in taxa distribution before and after the diet we analyzed the 
relative microbial abundance at diverse taxonomic levels for each subject; particularly, Fig. 29 
shows the results regarding the phylum level. We found no significant statistical difference at every 
level analyzed (phylum, family, genus), due to the huge heterogeneity of the these patients.  
 
Fig. 29 Bar charts representing the average relative abundance of fecal bacterial phyla of subjects before (t0) 
and after (t1) the ketogenic treatment. 
Then, we performed quantitative RT-PCR in order to validate the NGS data and evaluate possible 
changes in specific gut bacteria after one month of KD. We detected the microbial abundance of four 
bacterial groups, which are important for a good state of gut health: Enterobacteriaceae, as a marker 
of inflammatory status, Bifidobacterium spp., Roseburia intestinalis and Faecalibacterium prausnitzii, 
able to produce SCFA by fermentation of non-digestible carbohydrates. Results, expressed as 
genomes/g feces, are reported in Fig. 30. Data showed a decrease in Faecalibacterium prausnitzii after 
one month of KD, that was statistically significant (p = 0.0170). For the others bacteria analyzed we 
did not find any significant difference, however we saw a reduction-trend for Bifidobacterium spp. 
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Once again, the small number of subjects (7) and their heterogeneity constituted a limitation, as it 
was more difficult to detect significant differences before and after the ketogenic therapy. 
 
Fig. 30 Microbial abundance detected with RT-PCR of Enterobacteriaceae, Bifidobacterium spp., Roseburia 
intesinalis, and Faecalibacterium prausnitzii, before (t0 : orange) and after (t1: blue) the KD in 7 patients. 
4.2.2.4 SCFA decrease with KD 
We measured SCFA concentrations before and after KD; results are reported in Tab. 14. We found a 
significant statistical difference before (t0) and after (t1) the KD for total SCFA, acetate, butyrate and 
propionate (p < 0.05); on the contrary, iso-valerate and iso-butyrate were not statistically significant. 
Overall, the results showed that the KD strongly decrease the amount of SCFA in these patients, 
indicanting an alterated status of the gut microbiota, that is independed of the disease state. 
Furthermore, comparing these data with the results obtained from healthy controls samples, it 
appeared that SCFA concentrations of CTR and t0 were quite similar, instead a strong reduction of 
SCFA occurred in t1 samples, as Fig. 31 shows. 
Fecal SCFA (mg/g dry feces) 
 t0 t1  
 Mean SD Mean  SD p-value 
total SCFA 18.76 8.2 10.11 5.45 0.004 
Acetate 8.29 4.47 4.07 2.73 0.005 
Butyrate 4.77 2.33 2.84 1.5 0.008 
Propionate 4.09 1.72 2.27 1.24 0.028 
Iso-valerate 0.98 0.54 0.59 0.22 0.105 
Iso-butyrate 0.62 0.32 0.34 0.16 0.066 
Tab. 14 Fecal SCFA concentrations before (t0) and after one month (t1) of the beginning of the KD. Data are 
expressed as means ± standard deviation.  
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Fig. 31 Comparison between fecal SCFA concentrations of healthy controls (CTR), patients before (t0) and after 
one month (t1) of KD. Data are expressed as means ± standard deviation.  
4.2.2.5 Fecal water toxicity 
The toxicity of fecal water, an additional parameter of gut human health, was analyzed in our group 
of 7 patients. Firstly, we measured the citotoxicity by Trypan Blue assay (Fig. 32). Only one fecal 
water sample (3 t1) resulted citotoxic, as the percentage of viability was below 50% (43.1 ± 1), 
however all the other samples were not citotoxic. We decided to go further with the analysis and 
take into account also this sample, to confirm its level of toxicity. Additionally, we did not find any 
statistical significant difference before and after the KD for each subject. 
 
Fig. 32 Citotoxicity of fecal water before (t0, green) and after (t1, orange) the KD in 7 patients and in positive 
(red, H2O2) and negative (yellow, medium) controls. Data are expressed as mean ± standard deviations; * 
means p < 0.05. 
Afterwards, we measured fecal water genotoxicity with Comet assay; results are reported in Fig. 33 
as percentage of DNA in the tail. As expected, the subject with a high citotoxicity (sample 3) showed 
the highest genotoxicity, both before (t0) and after (t1) the KD; this result might be due to the 
particular clinical condition of the patient. The other subjects showed a medium level of 
genotoxicity, following the classification of Venturi et al. (1997) (range between 25.3 and 41.8%). 
Moreover, we detected significant statistically differences in 4 patients between t0 an t1 (samples 
2,4,5,6); the level of genotoxiciy decrease after the ketogenic therapy (2t0: 40.5 ± 2.8, 2t1: 28.6 ± 2.5; 
4t0: 31.9 ± 0.8, 4t1: 29.3 ± 1; 5t0: 41.8 ± 3.4, 5t1: 30.2 ± 0.8; 6t0 33.4 ± 0.3, 6t1 25.3 ± 2.9; p < 0.05) therefore 
KD could have an impact on human intestinal environment, at least in these patients. 
0 
5 
10 
15 
20 
25 
30 
35 
ACE PRO i-BUT BUT i-VAL TOT 
m
g
 /
 g
 f
ec
es
 
CTR 
t0 
t1 
0 
50 
100 
Controls 1 2 3 4 5 6 7 
%
 v
ia
b
il
it
y
 
t0 
t1 
* 
64 
 
 
Fig. 33 Genotoxicity of fecal water before (t0, green) and after (t1, orange) the KD in 7 patients, expressed as % 
of DNA in the tail (mean ± standard deviation); * means p < 0.05. 
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4.3 DISCUSSION 
The classic KD is a high-fat very low-carbohydrate diet, used worldwide for the treatment of 
refractory epilepsy, and increasingly applicated in different diseases such as GLUT1-DS and other 
metabolic or neurological disorders (Barañano & Hartman, 2008 – Veggiotti & De Giorgis, 2014). 
Patients stay on this diet for months or lifelong, but very few in vivo studies have been published in 
literature about KD global effects on human health. Moreover, it is well known that the diet is one of 
the most important external factor that strongly influence the composition of gut microbiota (Bibbò 
et al., 2016 – David et al., 2014 - De Filippo et al., 2010). It has been demonstrated that diet and 
derived microbial metabolites have strong implications with the development of food associated 
diseases including obesity, malnutrition, eating disorders, but also intestinal inflammatory diseases 
and colorectal cancer (Requena et al., 2018 – Yadav et al., 2018). Considering the unbalanced 
macronutrient composition of the KD, which is completely different from a conventional diet, it is 
possible that it might induce some changes in gut microbiota, which have been raraly studied in 
patients on ketogenic treatment for various pathological conditions. In addition to the fact that the 
number of in vivo studies about this argument is few, the results reported are not always 
comparable, both for type of pathologies considered and methodologies used. For these grounds, 
our study firstly focused on differed intestinal microbiota between healthy and epileptic or affected 
by GLUT1-DS patients; besides, the specific effect of KD, regardless of the disease, was investigated 
deeply through further analysis of gut microbiota before and after one month of KD treatment. 
The primary important outcome of the first part of our research is that the gut microbiota of patients 
differs significantly from that of healthy controls; this difference is supported by several analysis 
perfomed and described above. Our data suggest that the KD microbial population is reduced in 
richness and uniformity; indeed, both - and -diversity of KD and healthy microbiome differed 
significantly. The differences indicated shifts in composition of KD microbiome; in particular, 
-diversity expresses the mean species diversity in sites at a local scale, while -diversity quantifies 
the number of different communities in a sample dataset. A rich microbial ecology promotes the 
fundamental cross-talk and cross-feeding between species that guarantees the resilience of the gut 
ecosystem; conversely, one of the features of intestinal dysbiosis is the loss of diversity (Hubbel S.P., 
2001 - Whittaker R.H., 1972). Despite the small cohort enrolled, owing to the difficulties occurred 
during the recruitment (most of the patients affected by drug-resistant epilepsy and GLUT1-DS do 
not have fecal continence), our results are consistent with what was observed in other papers 
studying the microbiota alteration in patients undergoing a ketogenic treatment. For instance, a 
recent study by Swidsinski and collegues showed a reduced mass and diversity of the colonic 
microbiome in patients with multiple sclerosis on a KD (Swidsinski et al., 2017). An additional 
research reported lower gut microbiota diversity in infants affected by refractory epilepsy in 
comparison with healthy infants, as indicated by the Shannon index, a composite index that takes 
into account both richness and evenness of the bacterial (Xie et al., 2017). The same outcome has 
been observed also in a murine model of autism spectrum disorder, used in a study (Newell et al., 
2016) that showed an anti-microbial-like effect of KD by significantly decreasing total host bacterial 
abundance.  
At microbial composition level, in our KD cohort we found a strong reduction in Bacteroidetes and 
an increase in Firmicutes, compared to the healthy controls, indicating an altered status of gut 
microbiota. The phyla Bacteroidetes and Firmicutes include the most abundant bacterial division of 
the human gut microbiota (Qin et al., 2010). Dysbiosis between Firmicutes and Bacteroidetes in the 
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human gut has been described in previous studies in association with some disorders. For instance, 
an altered ratio Firmicutes/Bacteriodetes due to a lower level of Bacteriodetes was reported in obesity 
(Ismail et al., 2010 – Ley et al., 2006), but also inflammatory bowel disease (IBD) (Zhou & Zhi, 2016), 
and type 2 diabetes (Remely et al., 2013). This type of dysbiosis is associated to an inflammatory 
status which could have negative implications for host health. More important, our taxonomic 
analysis indicated that the altered ratio between Firmicutes/Bacteroidetes was due to a significant  
decrease in Bacteroidetes, and consequently in Bacteroidaceae and Bacteroides, in KD group compared 
to CTR. Although the effects of high-fat diets on gut have been investigated in different papers, the 
results are conflicting. A recent review reported that, in human intervention studies, the high fat 
intake could increase genera such as Bacteroides (Requena et al., 2018). On the other hand, in an 
animal study using mice fed with a standard carbohydrates diet and then switching to a high-fat 
diet, showed a decrease in Bacteroidetes and an increase in Firmicutes. This was seen for both 
genotypes (in the presence or abscence of obesity), indicating that this alteration was due to the 
high-fat diet itself, not to the obese state of the mice (Hildebrandt et al., 2009). Despite in literature 
there are not in vivo studies totally comparable to our research, the decrease in Bacteroidetes has been 
reported in other papers regarding the effect of KD on gut (Swidinski et al., 2017 - Xie et al., 2017), 
accordingly to our findings.  
Alterations in the abundance of microbial communities lead to changes in the quantity and quality 
of some microbial metabolites, such as SCFA. For this reason, in order to further investigate the 
dysbiosis highlighted in KD group, we determined the amount of SCFA with gas chromatography. 
To our knowledge, this is the first study that measures SCFA concentrations during a ketogenic diet 
treatment, as the papers published to date are focused exclusively on microbiota profiling. 
However, we believe that additional analyzes are appropriate to better assess the global effect of the 
KD on human gut. Our results showed a statistically significant decrease in total SCFA 
concentrations, and also for each SCFA except for butyrate, that showed a decreased-trend too, 
although not statistically significant (p = 0.08), in KD group compared to CTR. It is worthy of note 
that SCFA exert multiple beneficial effect on human energy metabolism (den Besten et al., 2013), 
thus, this trend implies an impaired metabolic activity which might be detrimental for human 
health. The reduction of SCFA has been shown in studies investigating the gut microbiota in 
different pathologies, such as anorexia nervosa (Borgo et al., 2017), Rett syndrome (Borghi et al., 
2017) and systemic inflammatory response syndrome (Yamada et al., 2015). The decrease in SCFA 
concentrations observed in our study, can be explained, firstly, as a consequence of the reduction in 
carbohydrates content, and consequently of the insoluble fiber, in the KD. In fact, it is recognised 
that non-digestible carbohydrate availability in the large intestine can shape the whole microbial 
community, and the reduced intake of fermentable dietary carbohydrate might impact on both the 
activity and the abundance of different bacterial group able to produce SCFA (Chassard & Lacroix, 
2013 - Kleesen et al, 2001 – Koropatkin et al., 2012). Therefore, the difference between KD and 
conventional diet with standard amount of carbohydrates (accordingly to the Italian Food-based 
Guidelines about 45-60% of total energy intake), and the low amount of fiber (about 8-9g/day in a 
KD, instead that 25g/day accordingly to the Italian Food-based Guidelines), could explain these 
results. Moreover, we found a decrease in Bacteroidetes phylum, which is mainly able to produce 
acetate and propionate (den Besten et al., 2013 – Rios Covian et al., 2017). Nevertheless, in this first 
step of the in vivo research, we compare patients undergoing a KD as a required therapy for their 
disease, with healthy subjects. Therefore it should be considered that the dysbiosis observed in KD 
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group, both for microbial populations and SCFA production, may be due to their pathological 
condition. 
In order to overcome this issue, the second step of our research has included the evaluation of the 
specific KD effect on the gut, regardless the pathology, by collecting samples before the diet and 
after one month. We selected 7 patients who have to begin the ketogenic treatment as a therapy and 
asked them to collect fecal samples in these two different time points, with the aim to assess 
variations before and after the diet in the same subject.  
Considering the data obtained from the microbiota profiling (-diversity, -diversity, taxonomy 
analysis), which showed differences between KD and healthy CTR group, but no variations within 
the same patient by comparing t0 versus t1, we investigated, in our cohort of 7 subjects, the 
microbial abundance of particular bacterial groups with quantitative RT-PCR. We choose four 
different bacteria in order to validate the NGS analysis and evaluate changes before and after the 
dietary treatment in this specific cohort of subjects; moreover, the bacterial groups selected were 
markers of inflammatory status (Enterobacteriacea) and fermentation activity (Bifidobacterium sp., 
Roseburia intestinalis, Faecalibacterium prausnitzii), to better investigate the status of gut health. After 
performing the analysis, we did not find any statistical significant difference in Enterobacteriaceae, 
Roseburia intestinalis and Bifidobacterium spp., although for the last one a decrease-trend was 
observed. Instead, we detected a significant reduction in Faecalibaterium prausnitzii, which is 
important for the fermentation of non-digestible carbohydrates and the production of SCFA, 
particularly of butyrate. These findings suggest that the low amount of fiber (8,7 ± 4,4 g/day during 
the diet) might alter the different fibrolytic species responsible for fiber fermentation, even if the 
reduction of these species was not uniform. 
We further measured the concentrations of SCFA before and after the KD, and we found that they 
were reduced after the dietary intervention. Moreover, we compared the results obtained from 
healthy subjects analysis to the diseased group not on a KD (t0 group), and we did not find 
differences (p = 0.51), as the SCFA concentatrions were quite similar. Instead, a strong reduction of 
SCFA was observed after one month of dietary therapy, as significant statistical differences were 
detected for acetate, proprionate and butyrate comparing the groups t0 versus t1. The significant 
decrease in butyrate, not showed in KD versus CTR, is consistent with the reduction in 
Faecalibacterium prausntizii in the 7 subjects analyzed. These important results mean that the change 
in microbiota composition and in markers of bacterial metabolism may be caused by a specific 
impact of the ketogenic protocol, beside the pathological condition of people required to follow this 
diet as a therapy. 
Additionally, we evaluated the toxicity of fecal water to better understand the global impact of the 
KD on human gut. We decided to analyze this aspect because diet could affect the composition of 
human feces thus determining intestinal environment and exposition of colon mucosa to risk factors 
(de Kok & van Maanen, 2000 – Mai et al., 2009). Therefore, Trypan blue test and Comet assay were 
performed with the aim to evaluate if the consumption of a KD, regardless to the pathological 
condition, might result in differences in fecal water cytotoxicity/genotoxicity. Since there is a high 
inter-individual variability of fecal water activity in the population (Erba et al., 2014 - Osswald et al., 
2000), we choose to perform these experiments only for the cohort of 7 subjects to assess the effect of 
the diet, not the level of toxicity in a healthy group. Actually, previous studies evaluated the toxicity 
using the same subject before the dietary treatment as the control, since it is the most accurate way 
to assess the specific effect of the diet itself (Erba et al. 2012 – Woods et al., 2002). Results showed that 
the majority of samples were included in the medium genotoxicity category, except for one subject 
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(number 3) who displayed the highest citotoxicity and consequently genotoxicity. This apparently 
“outlier” data is due to the particular clinical condition of the patient, since, in addition to be 
epileptic, he was affected by celiac disease. Although the patient followed a gluten-free diet before 
the dygnosis of epilepsy, it could not be enough to restore its inflammatory status, and this might be 
the reason explaining the more damaged colon mucosa and the higher value of fecal water toxicity. 
These findings confirmed the quality of the genotoxicity marker, as the % of DNA damage was 
consistent with the level of citotoxicity. Moreover, we found a decrease-trend of genotoxicity level 
after one month of ketogenic diet; actually, data showed a significant statistical reduction in four 
subjects. We hypothesized that this effect may be due to the effectiveness of the ketogenic therapy, 
which improves the overall health condition of these patients. However, the findings obtained in 
this study are comparable with others detected in healthy Italian people (Erba et al., 2014), which 
showed similar level of genotoxicity of fecal water (medium level of genotoxicity). Thus, 
accordingly to our results, it seems that neither neurological or metabolic pathologies not the KD 
could adversely affect the level of fecal water toxicity in our cohort. 
4.4 CONCLUSIONS 
In conclusion, we found that, first of all, the microbiota gut composition of patients affected by 
refractory epilepsy or GLUT1-DS undergoing a KD as a therapy, was significantly different than 
healthy control subjects, thus it is possible that KD may influence human gut. Moreover, KD group 
showed an intestinal dysbiosis, highlighted by reduced biodiversity and richness in microbial 
populations. In addition, we found an altered ratio Firmicutes/Bacteroidetes, due to a significant 
decrease of Bacteroidetes phylum in KD group, consistent with the status of dysbiosis. 
This study was the first to evaluate the SCFA concentrations in relation with the consumption of a 
ketogenic dietary protocol; we found lower levels of SCFA in KD group compared to CTR, but also 
analyzing the same subjects before and after the diet. These data underline how KD is able to affect 
gut health by altering microbiota composition and its metabolic activity. This can mainly be due to 
reduction in carbohydrates content, and in bacterial genera able to do fermentation, like 
Fecalibaterum prausnitzii and Bacteroides.  
Both citotoxicity and genototixicy of fecal water analyzes have shown that ketogenic treatment does 
not adversely affect human colon mucosa, as the results indicated medium level of toxicity, 
comparable with levels found in other studies of healthy population. 
There are some limitations that need to be clarified. Firstly, the small size of the group of the 
partecipants due to the difficulties encountered during the recruitment of the subjects. Beside the 
rarity of the pathologies considered, most of the patients affected by drug-resistant epilepsy or 
GLUT1-DS do not have fecal continence, thus it was not possible to ask them to collect biological 
samples. Secondly, it would be appropriate to evaluate the effect of KD on human gut for longer 
time of follow-up, as other studies (Newell et al., 2016 - Swidinski et al., 2017) reported a 
re-estabilishment of the dysbiosis condition after several weeks of ketogenic dietary treatment. 
Although the limits described, this study allow us to conclude that KD has an impact on the human 
gut, highlighting the need for further research to avoid long-term effects and optimize the therapy. 
Considering our findings, it may be reasonable to suggest a supplementation of 
probiotics/prebiotics to potentially restore the microbiota stability. 
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5 CONCLUSIONS  
In conclusion, through this Ph.D. thesis it was possible to provide novel results about the effects of 
KB and ketogenic dietary treatment. These findigs are particular important if we consider the 
increasing use of this diet for different purposes, not only as a therapy for refractory epilepsy.  
In the first part of the research, we provided data on the vascular risk represented by KD-induced 
oxidative stress using an in vitro model of endothelium. We demonstrated that KB might have an 
impact on cell metabolism in tissue functions different from the neurological one. The mechanism 
hypothesized in our in vitro study is that KB could activate the transcription factor Nrf2, which 
improves the cellular ability to remove harmful substances by the activation of cellular defence 
processes. However, the activation of Nrf2 is the result of impaired oxidative cell status, therefore it 
could be harmful to promote this metabolic response in the long term.  
In the second part of the research, an in vivo study was performed to verify the impact of the KD on 
human gut. The primary important outcome was that, comparing patients following a KD with 
healthy subjects, the microbiota composition was signficanlty different, characterized by a status of 
dysbiosis. For the first time in this field of research the SCFA concentrations in relation with the 
consumption of a KD were evaluated. We found lower levels of SCFA in KD group compared to 
controls, but also analyzing the same subjects before and after the diet. Thus, KD is able to affect gut 
health by altering microbiota composition and its metabolic activity. This can mainly be due to the 
reduction of carbohydrates and fiber content, and of bacterial genera able to do fermentation. 
Finally, the analysis of fecal water toxicity showed that ketogenic treatment did not adversely affect 
human colon mucosa. 
In the end, everytime a KD is applied, both for therapeutic or weight loss purposes, a careful 
examination of the risk-benefit ratio should be done. There is a need for further research in order to 
avoid long-term effects of this diet and optimize the therapy in different pathologies. 
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23th Workshop on the Developments in the Italian PhD Research on Food Science Technology 
and Biotechnology, 19-21 Septmber, Oristano, Italy. 
Metabolic effects of dietary approaches: ketone bodies & ketogenic diet 
Meroni Erika  
Department of Food, Enviromental and Nutritional Sciences, University of Milan, Milan, Italy 
This PhD thesis dealt with the investigation of the metabolic effects of ketone bodies (KB), produced 
during a ketogenic diet (KD). The work was structured in two main projects. Firstly, we assessed, 
with an in vitro model of endothelium, the vascular risk represented by KD-induced oxidative 
stress, by studying the cito- and geno-toxicity of KB and the activation of a cellular response after 
KB exposure. Afterwards, the in vivo impact of therapeutic ketogenic diet on human intestinal 
environment has been verified, by the evaluation of several parameters: toxicity of fecal water, 
markers of bacterial metabolism and composition of gut microbiota composition. The results of this 
thesis contribute to improve knowledge about the mechanisms of action of the KD and its global 
effect on human health. 
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15th International Conference on Clinical Nutrition, 24-26 May, Vienna, Austria. 
Metabolic responses in endothelial cells following exposure to ketone bodies 
Meroni E1, Papini N2, Criscuoli F1, Casiraghi MC1, Massaccesi L3, Basilico N4, Erba D1. 
1Department of Food, Enviromental and Nutritional Sciences, University of Milan, Milan, Italy 
2Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, 
Italy 
3Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy 
4Department of Biomedical Sciences, Surgical and Dental Sciences, University of Milan, Milan, Italy 
The ketogenic diet (KD) is a high-fat, low-carbohydrate diet based on the induction of the synthesis 
of ketone bodies (KB). Despite its multiple applications, the impact of KD on the human body is not 
completely understood The purpose of this study was to evaluate in vitro the biological effects of 
KB on HMEC-1 endothelial cells. The exposure of cells to KB exerted a moderate genotoxic effect, 
measured by a significant increase in DNA oxidative damage (p<0.001) that was not related to the 
duration of exposure (2-48 h). To investigate the ability of KB to modulate DNA susceptibility to 
oxidative stress, we exposed cells to a secondary oxidative insult (H2O2) after KB supplementation. 
Surprisingly, cells treated with KB for 48 h showed significantly less DNA damage compared to 
control oxidized cells. One possible mechanism by which this protection might occur is through the 
activation of the Nrf2 pathway. In KB-treated cells, we found increased levels of Nrf2 in nuclear 
extracts and higher gene expression of HO-1, a target gene of Nrf2, compared to control cells. These 
results suggest that KB induce moderate oxidative stress, which activates the transcription factor 
Nrf2 and induces the transcription of target genes involved in the cellular antioxidant defense 
system. Consequently, in endothelial cells, the metabolic responses to KB-induced stress via Nrf2 
pathway activation makes cells more resistant to a secondary insult, in this case H2O2, leading to a 
reduction in DNA oxidative damage. 
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15th International Conference on Clinical Nutrition, 24-26 May, Vienna, Austria. 
Formulating orange oil-in-water beverage emulsions for effective delivery of bioactives: influence of carrier oil 
type on chemical stability, antioxidant activity and in vitro bioaccessibility of lycopene 
Meroni E1, Raikos V2. 
1Department of Food, Enviromental and Nutritional Sciences, University of Milan, Milan, Italy. 
2Rowett Institute, University of Aberdeen, Aberdeen, Scotland, UK. 
The carotenoids inclusion in diet is considered to contribute to human health, as their antioxidant 
properties are associated with a reduced risk for the development of chronic diseases. Thus, the 
consumption of lycopene, which is the most predominant carotenoid in human plasma, is 
important for various biological functions. The addition of lycopene in food formulations is 
problematic because of its lipophilic nature and high susceptibility to oxidation. However, its 
bioavailability can increase when co-ingested with other lipids. A popular method for increasing 
carotenoid bioavailability is emulsification. The purpose of the present work was to develop an 
edible orange oil-in-water beverage emulsion containing lycopene as a bioactive ingredient. 
Particularly, the influence of carrier oil type on the chemical stability, antioxidant properties and 
bioaccessibility of lycopene in orange oil-in-water beverage emulsions was investigated. The 
emulsions were formulated with orange oil (A), which was partially (50%) replaced with tributyrin 
(B) or corn oil (C). The addition of corn oil enhanced the physical stability of the beverage during 
chilled storage by inhibiting Ostwald ripening. The formation of oxidation products was 
insignificant during storage for 28 days at 4 °C, regardless the type of added oil. Lycopene was more 
susceptible to chemical degradation in the presence of unsaturated, long chain triglycerides and the 
retention followed the order: A (87.94%), B (64.41%) and C (57.39%). Interestingly, bioaccessibility of 
lycopene was significantly lower for emulsions formulated with 50% corn oil as opposed to 100% 
orange oil as indicated by the simulated in vitro gastric digestion model. 
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5th International Conference on Foodomics: from Data to Knowledge, 10-12 January, Cesena, 
Italy. 
Effects of sub-lethal concentrations of silver nanoparticles on Caco-2 cells  
Meroni E1, Domingo G2, Erba D1, Cattò C1, Cappitelli F1, Vannini C2, Bracale M2 
1Department of Food, Environmental and Nutritional Science - Università degli Studi di Milano - 
Milano - Italy 
2Department of Biotechnology and Life Sciences - Università degli Studi dell’Insubria - Varese - Italy 
Nanoparticles (NPs) are widely used in the agri-food industry as additives, for example for 
functionalizing food processing surfaces and for packaging, to improve mechanical and 
antimicrobial properties. Given these widespread applications, NPs exposure represents a potential 
toxicological risk for human health. Of special interest is the effect of NPs on human gut microbiota, 
considering the range of consumer goods that can be intentionally, or accidentally ingested.  
In this research, the metabolic response of Caco-2 intestinal cells exposed to sub-lethal 
concentrations of silver nanoparticles (AgNPs) has been investigated. In order to understand the 
complex interplay among AgNPs, gut biofilm and its host, an experimental model which 
reproduces an interactive gut ecosystem was developed. This simplified system was composed by 
Escherichia coli mono-species biofilm and Caco-2 monolayer. Interaction between the two 
compartments was obtained by exposing Caco-2 intestinal cells to the metabolites produced by E. 
coli biofilm after its exposure to AgNPs.  
A label-free quantitative proteomic analysis, performed on Caco-2 monolayers treated for 24 hours 
with AgNPs (1mg/L) or metabolites produced by biofilm after its exposure to AgNPs, showed 
several differentially expressed proteins (DEPs). Respect to the control, we found 40 up-regulated 
and 260 down-regulated proteins after AgNPs treatments whereas, in Caco-2 cells treated with 
biofilm metabolites, we detected 175 up-regulated and 226 down-regulated proteins. Taking 
advantage of bioinformatics tools and over-represented Gene Ontology (GO) categories, DEPs were 
annotated into functional categories and metabolic pathway involved. Proteomic analysis showed 
that AgNPs and biofilm metabolites have different mechanism of action, highlighting the 
importance of the biofilm on the fate and toxicity of silver nanoparticles. 
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38th National Congress SINU (Italian Society of Human Nutrition), 20-22 November, Torino, 
Italy. 
Stabilità fisico-chimica, proprietà antiossidanti di bevande addizionate con -carotene e bioaccessibilità del 
carotenoide: influenza della tipologia di olio carrier. 
Meroni E1, Raikos V2 
1Dipartimento di Scienze per gli Alimenti, la Nutrizione, l’Ambiente, Università degli Studi di 
Milano, Milano 
2Rowett Institute, Università di Aberdeen, Aberdeen, Scozia, UK    
Premesse Il consumo di -carotene è importante per varie funzioni biologiche e non solo per essere 
un precursore della vitamina A. L'aggiunta di -carotene nelle formulazioni alimentari è 
problematica a causa della sua lipofilia e della sua alta suscettibilità a luce, ossigeno, temperatura e 
pH. Tuttavia, la sua biodisponibilità può aumentare se co-ingerito con altri lipidi. 
Obiettivo Indagare l'effetto di differenti oli carrier del -carotene, in bevande contenenti: 92% 
acqua, 3% proteine di siero di latte, 4% olio, 0,7% acido citrico e 0,5% -carotene.   
Metodi Sono state preparate tre bevande con diverse fasi olio: A) 100% olio di arancio B) 50% olio di 
arancio + 50% tributirina (trigliceridi a catena corta = SCT) C) 50% olio di arancio + 50% olio di mais 
(trigliceridi a catena lunga = LCT) e sono state valutate: 1) stabilità fisica (Turbiscan) e 2) shelf life 
(HPLC) dopo quattro settimane di stoccaggio a 4°C; 3) proprietà antiossidanti (FRAP, TBARS, dieni 
coniugati) e 4) bioaccessibilità di -carotene (digestione gastro-intestinale in vitro). 
Risultati Le bevande formulate con 50% di LCT sono fisicamente più stabili rispetto a quelle con 
50% di SCT. Non è stata osservata alcuna degradazione del β-carotene durante lo stoccaggio, 
indipendentemente dalla composizione della fase olio. La formazione di prodotti di ossidazione 
primaria e secondaria alla fine dello stoccaggio è risultata non significativa. La bioaccessibilità del 
β-carotene è sensibilmente influenzata dal tipo di olio carrier e diminuisce nell'ordine C > B > A. 
Conclusioni La tipologia di olio carrier ha un impatto significativo sulle proprietà fisico-chimiche 
delle bevande addizionate con β-carotene. Si ipotizza che l'aumento della bioaccessibilità del 
carotenoide (~ 30%) nelle bevande formulate con LCT sia dovuto alla maggiore capacità di 
solubilizzazione delle micelle dopo il protocollo di digestione in vitro. 
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22nd Workshop on the Developments in the Italian PhD Research on Food Science Technology 
and Biotechnology, 20-22 September, Bolzano, Italy. 
Metabolic effects of dietary approaches: ketone bodies & ketogenic diet 
Meroni Erika  
Department of Food, Enviromental and Nutritional Sciences, University of Milan, Milan, Italy 
The first part of the PhD thesis project is an in vitro study. Its aim was to investigate the effects of 
exposure to ketone bodies (KB) in HMEC-1 endothelial cells by measuring markers of oxidative 
stress. In particular, it was evaluated: 1) the DNA oxidative damage by Comet assay in order to 
study the genotoxicity due to KB; 2) the effect of a secondary oxidative insult after exposure to KB; 
3) the activation of Nrf2 pathway, which is a transcriptional factor involved in the cellular response 
to a stress, by western blot and real time PCR. 
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37th National Congress SINU (Italian Society of Human Nutrition), 30 November-2 December, 
Bologna, Italy. 
Effetti dell’esposizione ai corpi chetonici in cellule endoteliali 
Meroni E1, Papini N2, Erba D1. 
1Dipartimento di Scienze per gli Alimenti, la Nutrizione, l’Ambiente, Università degli Studi di 
Milano, Milano 
2Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, 
Segrate (MI) 
Premesse La "dieta chetogenica" (KD) è un programma alimentare progettato negli anni '20 come 
terapia per l'epilessia farmaco-resistente, e che si è diffuso, a partire dagli anni '70, come una dieta 
dimagrante (Atkins). Gli effetti "in vivo" delle KD sono argomento di discussione, non tanto per le 
finalità terapeutiche, quanto per la salubrità di questi approcci dietetici formulati per la rapida 
perdita di peso.  
Obiettivi Indagare, in cellule endoteliali HMEC-1, gli effetti dell’esposizione a concentrazioni 
fisiologiche di corpi chetonici (KB).  
Metodi Dopo aver esposto le cellule ai , è stato valutato il danno ossidativo al DNA (Comet 
Assay) conseguente a differenti tempi di esposizione (2h, 24h e 48h), ed il danno al DNA 
determinato da uno stimolo ossidativo (H2O2) applicato successivamente tali esposizioni.  
Risultati L’esposizione ai KB esercita un moderato stress rilevabile da un significativo aumento del 
danno ossidativo al DNA a partire dalle 2 ore (20% DNA nella coda) senza mostrare un ulteriore 
aumento significativo ai tempi successivi. L’insulto ossidativo applicato dopo 2 h di esposizione, 
aumenta significativamente il danno al DNA (60% di DNA nella coda), mentre le cellule trattate con 
KB per 48h mostrano, dopo stress ossidativo con H2O2, un danno  significativamente inferiore 
(40% di DNA nella coda, p<0.001).   
Conclusioni I risultati ottenuti suggeriscono che l’esposizione delle HMEC-1 ai KB determini una 
condizione di lieve stress ossidativo che, stimolando le difese antiossidanti della cellula, la 
renderebbe più protetta verso stress successivi. Si ipotizza l’attivazione di qualche fattore di 
trascrizione coinvolto nella risposta cellulare allo stress ossidativo.   
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21th Workshop on the Developments in the Italian PhD Research on Food Science Technology 
and Biotechnology, 14 -16 September, Portici, Italy. 
Metabolic effects of dietary approaches: ketone bodies & ketogenic diet 
Meroni Erika  
Department of Food, Enviromental and Nutritional Sciences, University of Milan, Milan, Italy 
The overall aim of this PhD project is to investigate the metabolic effects of ketone bodies, in 
particular -hydroxybutyrate and acetoacetate, by “in vitro” and “in vivo” studies. The main 
objectives will be: 1) to verify the effects exerted by ketone bodies on cellular responses, by studying 
the activation of transcriptional factors (like Nrf2) and post-translation changes of proteins; 2) to 
verify the impact of this dietary approach on human intestinal environment, by evaluation of 
composition of gut bacteria, marker of bacterial metabolism and toxicity of fecal water. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
6.3 Awards 
Best Oral Presentation – Young Researchers Forum at the 15th International Conference on Clinical 
Nutrition, Vienna, Austria, 24 – 26 May 2018. 
Best Poster Award at the 15th International Conference on Clinical Nutrition, Vienna, Austria, 24 – 26 
May 2018. 
Young Researchers Award for the best poster presentation at the National Meeting of Italian Society of 
Human Nutrition (SINU), Bologna, Italy, 30 November -2 December 2016. 
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6.4 Ph.D Erasmus Traineeship 
Erasmus Traineeship: The Rowett Institute of Nutrition and Health, University of Aberdeen, 
Aberdeen, UK. January – May 2017.  
Traineeship title: Physicochemical stability, antioxidant properties and bioaccessibility of 
beta-carotene and lycopene in beverage emulsions: influence of carrier oil type 
Detailed programme of the traineeship: Carotenoids are a group of more than 600 lipophilic 
compounds that contribute to the yellow, orange and red colours of fruits and vegetables, and their 
inclusion in the diet is considered to contribute to human health and well-being. The main objective 
of this study is to develop an edible orange oil-in-water beverage emulsion containing beta-carotene 
or lycopene, in which the oil phase is partially replaced by long chain triglycerides or small chain 
triglycerides in order to investigate the influence of carrier lipid on several parameters affecting the 
bioaccessibility of the lipophilic bioactive compound. In particular, the specific objectives are: 1) to 
verify the physicochemical stability of the emulsions under four weeks of chilled storage; 2) to 
evaluate their antioxidant properties and 3) to assess the bioaccessibility of beta-carotene by using 
an in vitro gastro-intestinal digestion model. 
COPIES OF PAPER PUBLISHED: 
Meroni E., Raikos V. Lycopene in beverage emulsions: optimizing formulation design and 
processing effects for enhanced delivery. Beverages, 2018, 4(1), 14; DOI:10.3390/beverages4010014. 
Meroni E., Raikos V. Formulating orange oil-in-water beverage emulsions for effective delivery of 
bioactives: improvements in chemical stability, antioxidant activity and gastrointestinal fate of 
lycopene using carrier oils. Food Res Int, 2018, 106, 439-445, DOI: 10.1016/j.foodres.2018.01.013. 
Meroni E., Raikos V. Physicochemical stability, antioxidant properties and bioaccessibility of 
β-carotene in orange oil-in-water beverage emulsions: influence of carrier oil type. Food Funct, 2018, 
9(1), 320-330, DOI:10.1039/C7FO01170A. 
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